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ABSTRACT 
Andrew Satterlee: Applications For a Radio-Theranostic Nanoparticle With High Specific Drug Loading 
(Under the direction of Leaf Huang)  
 
Since its initial publication over four years ago, the Lipid-Calcium-Phosphate (LCP) nanoparticle 
platform has shown success in a wide range of treatment strategies, encapsulating small molecules, 
peptides, and nucleic acids for cancer therapy. recently including theranostics.  Herein, we describe how 
this platform was used to encapsulate and deliver several radiometals for cancer therapy and imaging, 
including 177Lu, 90Y, and 64Cu.  Characterization of 177Lu-LCP has shown that radionuclide loading can be 
increased by several orders of magnitude without affecting the encapsulation efficiency or the 
morphology of 177Lu-LCP, allowing consistency during fabrication and overcoming scale-up barriers 
typical of nanotherapeutics.  The choice of 177Lu as a model radionuclide has allowed in vivo anticancer 
therapy in addition to radiographic imaging via the dual decay modes of 177Lu.  Tumor accumulation of 
177Lu-LCP was measured using both SPECT and Cerenkov imaging modalities in live mice, and treatment 
with just one dose of 177Lu-LCP showed significant in vivo tumor inhibition in two subcutaneous 
xenograft tumor models.  Microenvironment and cytotoxicity studies suggest that 177Lu-LCP inhibits 
tumor growth by causing apoptotic cell death via double-stranded DNA breaks while causing a 
remodeling of the tumor microenvironment to a more disordered and less malignant phenotype.   
Although smaller tumors show a favorable response when treated with 177Lu-LCP, aggressive, 
desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial 
pressure, and resistant tumor microenvironment.  We have developed a combination therapy that can 
significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor 
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center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the 
accumulation and retention of nanoparticles in the tumor.  The vascular disrupting agent CA4P is able to 
increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the 
retention of these delivered radioisotopes is maintained over several days.  We use ultrasound to 
measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic 
isotope 177Lu as a therapeutic agent as well as a means to measure nanoparticle accumulation and 
retention in the tumor.  This combination therapy induces prolonged apoptosis in the tumor, decreasing 
both the fibroblast and total cell density and allowing further tumor growth inhibition using a cisplatin-
containing nanoparticle. 
Of course, clinical implementation of this combination therapy must be modified to minimize 
systemic toxicity.  While intravenous administration of radiation-labeled LCP presents a good model of 
internal radiation therapy’s effectiveness in combination with CA4P, the well-known uptake of 
nanoparticles into clearing organs presents a compelling argument against this injection route.  Perhaps 
the best future use for 177Lu/90Y-LCP is in a modified form of selective internal radiation therapy (SIRT), in 
which the nanoparticles are locally delivered to hepatic tumors via catheterization of the hepatic artery.  
Combination therapy with CA4P against desmoplastic tumors would not only cause massive apoptosis in 
the tumor centers, but also induce an increased accumulation of nanoparticles in the tumor and prime 
the microenvironment for further treatment. 
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CHAPTER 1: CURRENT AND FUTURE THERANOSTIC APPLICATIONS OF THE LIPID-CALCIUM-
PHOSPHATE NANOPARTICLE PLATFORM1 
 
1.1: Summary 
Since its initial publication over four years ago, the Lipid-Calcium-Phosphate (LCP) nanoparticle 
platform has shown success in a wide range of treatment strategies, recently including theranostics.  
The high specific drug loading of radiometals into LCP, coupled with its ability to efficiently encapsulate 
many types of cytotoxic agents, allows a broad range of theranostic applications, many of which are yet 
unexplored.   In addition to providing an overview of current medical imaging modalities, this 
introduction highlights the current theranostic applications for LCP using SPECT and PET, and discusses 
potential future uses of the platform by comparing it with both systemically and locally delivered clinical 
radiotherapy options as well as introducing its applications as an MRI contrast agent.  Strengths and 
weaknesses of LCP and of nanoparticles in general are discussed, as well as caveats regarding the use of 
fluorescence to determine the accumulation or biodistribution of a probe. 
1.2: Introduction 
The fields of tumor imaging and cancer therapy have been steadily sliding closer together since 
the field recognized a need for targeted therapeutics.  Targeted delivery must be coupled with 
verification of payload deposition in order to effectively monitor and analyze therapeutic outcomes.  A 
wealth of theranostic agents have been developed to address the growing desire for this dual-purpose 
                                                          
1 This chapter has been modified from its original appearance as a review article in Theranostics.  The original 
citation is as follows: Satterlee A and Huang L.  Current and Future Theranostic Applications of the Lipid Calcium-
Phosphate Nanoparticle Platform.  Theranostics.  2016; 6(7): 918-929.  doi:  10.7150/thno.14689 
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paradigm, and nanoparticle formulations have recently come to the forefront of theranostic research[1, 
2].   
Calcium phosphate precipitates have been used as in vitro transfection agents since the 
1970s[3], when it was discovered that DNA could be co-precipitated in a solution containing calcium 
chloride and phosphate-buffered saline.  Since that time, there has been a substantial effort to control 
particle size and aggregation in order to increase transfection efficiency and allow delivery in vivo.  Some 
formulation strategies gained moderate success in vitro[4-6], but it was not until 2010 that calcium 
phosphate nanoparticles were successfully coated with a lipid bilayer[7], and not until 2012 that these 
so-called Lipid-Calcium-Phosphate (LCP) nanoparticles showed efficient gene silencing in vivo[8].  Since 
that time, the two seminal papers have garnered nearly 300 citations, inspiring many other laboratories 
to use LCP themselves or innovate on its design[9-14].  The Huang lab has published nearly 20 original 
research articles using LCP, due to its versatility in encapsulating many types of therapeutic compounds, 
such as small molecule drugs[15-17], siRNA[18-22], DNA[23], peptides[24], and radionuclides[25, 26].  
The principles behind LCP formulation have also allowed the Huang lab to formulate lipid-coated 
nanoparticles with cores entirely made of cisplatin[27, 28].  Over the last six years, LCP has transitioned 
from a novel formulation to a powerful tool used to probe for answers regarding PEGylation 
kinetics[29], the tumor microenvironment[15, 18, 24, 25], cancer vaccines[18, 24], and gene 
therapy[23].  The Huang lab has now begun using LCP as a theranostic agent, using imaging modalities 
such as SPECT and PET.  
LCP is formulated using a reverse (water-in-oil) microemulsion system.  In separate round-
bottom flasks, water droplets containing either calcium or phosphate are stirred in an oil phase 
containing cyclohexane and the surfactant igepal.  The surfactant maintains the oil-water interface and 
stabilizes nano-sized water droplets in the oil.  When the two emulsions are mixed and the separate 
droplets collide, the soluble calcium and phosphate react to form nanoprecipitates, still suspended in 
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the water droplets.  Addition of the phospholipid DOPA soon after mixing allows the formation of a 
single lipid layer at the oil-water interface in which the hydrophilic head of DOPA inserts inside the 
water droplet and its hydrophobic tail remains in the oil phase.  The phosphate head group of the DOPA 
co-precipitates into the calcium-phosphate nanoprecipitate, positioning the hydrophobic tail to remain 
in the oil.  Over time, the co-precipitated DOPA replaces more and more igepal in the water-oil 
interface, and eventually the calcium phosphate precipitates are so well coated with DOPA that they are 
able to be dissolved in organic solvents such as chloroform or dichloromethane after washing with 
ethanol.  The final LCP nanoparticle, shown in Figure 1.1, is generated by adding free lipids such as 
DOTAP, cholesterol, and DSPE-PEG2000, also in organic solvent, to the cores.  The solvent is then 
evaporated to leave a thin film of lipids and cores on the edge of the vial.  Addition of warm 
water/sucrose solution and brief sonication is all that is needed to resuspend the final particles for 
testing or injection into mice.   
Encapsulation of therapeutics into LCP occurs during the calcium-phosphate nanoprecipitation 
portion of the procedure.  Phosphorylated prodrugs, nucleotide mimics, siRNA, and DNA are all ideal 
candidates for encapsulation into LCP because the phosphate groups on all of these molecules will co-
precipitate in the calcium-phosphate LCP core.  Radionuclides such as indium and lutetium can similarly 
be encapsulated via their low solubility with phosphate.  Because calcium-phosphate is acid-sensitive, 
after the LCP is delivered to the cellular endosome, the late endosome’s acidic environment will dissolve 
the calcium-phosphate core[7].  The increase in endosomal salt concentration increases the osmolarity 
in the endosome, destabilizing it and releasing the therapeutics into the cytosol.  The cell avoids 
calcium-induced toxicity by quickly lowering cytosolic calcium via the mitochondrial calcium uniporter 
and then by more slowly removing the excess intracellular calcium via the plasma membrane calcium 
ATPase[30]. 
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Herein we aim to review current imaging techniques and compare the theranostic capabilities of 
LCP to clinical practices that combine therapy and imaging.  This review will focus its discussion on the 
nuclear imaging modalities SPECT and PET. 
1.3: Single Photon Emission Computed Tomography (SPECT) 
SPECT imaging detects γ photon emissions from a decaying radioactive source inside the 
body[31].  Radionuclides with a high abundance of γ decay at energies around 100-200 keV[32], such as 
111In, 99mTc, and 123I, are ideal for detection using SPECT, as their γ energies are high enough to avoid 
attenuation in tissue but low enough to be adequately captured by the SPECT detectors.  Because the 
source emits photons in all directions, in order to maximize spatial resolution, a collimator must be used 
to block all photons that are not approaching the detector from the region or angle of interest.  More 
selective collimators increase the resolution of the image but also reduce signal to the detectors, 
requiring longer detection times or higher doses of radionuclide to maintain adequate image 
reconstruction[33]. SPECT is often run in combination with a computed tomography (CT) scan to provide 
anatomical contrast.   
1.4: Positron Emission Tomography (PET) 
PET imaging is similar to SPECT imaging, as the PET detectors also detect γ photons from a 
radioactive source inside the body[32].  In contrast to SPECT, the photons detected in PET are generated 
from an annihilation reaction between a positron emitted by the source and a nearby electron present 
in the body.  The annihilation reaction converts the electron-positron pair into 511 keV photons that 
travel in opposite directions toward the PET detector.  By only counting photon pairs that are detected 
at a 180o angle from each other, all other noise not attributed to positron emission can be disregarded, 
eliminating the need for collimation.  By also calculating the small differences in detector arrival time of 
the photon pair—referred to as time-of-flight—, more accurate spatial localization of the radionuclide 
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can be determined[34].  The unique imaging properties of positron emitters allow PET imaging to be 
more sensitive than SPECT, but PET must also be coupled with an imaging modality like CT or MRI for 
anatomical contrast. 
Comparing two common PET agents, copper-64 (64Cu) and gallium-68 (68Ga), will demonstrate 
the additional considerations that must be made when planning a PET imaging study.  Half-life must first 
be considered, as many PET agents have very short half-lives and must be produced and purified on-site.  
64Cu has a relatively long half-life of 12.7 h, allowing it to be shipped overnight without decaying 
prohibitively, unlike 68Ga which has a half-life of just 68 minutes.  Fortunately, 68Ga is generated by the 
slow decay of Germanium-68 (68Ge) and can be quickly purified from its parent on-site[35], unlike 64Cu 
which must be generated by neutron or proton bombardment in a nuclear reactor or cyclotron[36].  
Half-life also affects the total dose of nuclide that must be given to achieve the same decay rate during 
imaging.  It is desirable to inject a low total dose with a high rate of decay such that a large portion of 
the decay will occur during the imaging experiment.  In a one-hour PET imaging session using 68Ga, half 
of the remaining 68Ga atoms will decay during the imaging experiment, but if 64Cu is used, less than 10% 
of the 64Cu will decay during the experiment, leaving the rest to decay over the next few days.  In order 
to produce the same quality image, both 64Cu and 68Ga need to be dosed at similar positron decay rates, 
and since 68Ga decays more quickly, fewer total atoms also need to be given, further lowering the 
required dose.   
The energy with which a positron is emitted, β+max = 653 keV for 64Cu and β+max = 1899 keV for 
68Ga, also affects the resolution of the image.  A positron must be at rest energy before annihilating with 
an electron, and any extra energy is released as the positron proceeds away from its parent nucleus and 
collides with other matter[37].  Positrons ejected at higher energies must release more energy before 
annihilation and therefore must travel further away from the nucleus before the resulting two γ photons 
are generated.  Because the PET detectors can only detect where in space the photons were generated, 
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and not where the positron was emitted, a longer positron range will generate larger areas between the 
positron emitter and the photon generation, thus decreasing the spatial resolution of the image.  The 
average positron ranges in water for 64Cu and 68Ga are 0.55 mm and 2.8 mm, respectively[38], which is 
not a negligible difference and should be considered when planning an experiment.   
1.5: Clinical Nuclear Imaging 
In the clinic, SPECT and PET contrast agents are often used diagnostically for blood vessel 
perfusion imaging or tumor diagnosis.  Radiometals have recently seen more use in the clinic, and are 
often chelated to small molecules or targeted proteins. A huge amount of effort has gone into 
discovering bifunctional chelators that stably bind both the radiometal and the tumor-targeting 
moiety[39-43].  Because each radiometal ion can differ in atomic size, oxidation state, and electron 
configuration, a chelator that stably binds one metal may not be suitable for another.  Stability tests 
must include exposing the chelated metal to serum conditions, as an inadequate chelator may have 
higher affinity for an endogenous metal ion or allow reduction of its metal into a less stable state[44].  
The expected circulation time of the radionuclide must also be considered, as a nuclide chelated to a 
protein with a circulation half-life on the order of days would need a much more stable chelator than 
one on a particle with a half-life of an hour or less.  If an unsuitable chelator is chosen to bind a 
radionuclide, the nuclide may prematurely shed in circulation and skew the biodistribution data, as 
highly charged heavy metals such as 111In(III) or 177Lu(III) prefer to accumulate in the bone, and actively 
metabolized metals such as copper may be filtered through the liver and into the intestines.     
There are several typical radioisotopes used diagnostically as SPECT and PET contrast agents.  
Current clinical uses involve chelation or conjugation of the isotopes to small molecules for blood vessel 
perfusion imaging or tumor diagnosis.  Classically, the γ emitter 99mTc has been injected intravenously 
into patients after chelation to one of several small molecules such as exametazime and sestamibi[45].  
The lipophilic conjugate formed can accumulate in tumors and allow detection of many types of cancer 
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via SPECT.  In several clinical trials, 99mTc has also been conjugated to the apoptosis marker Annexin V to 
gauge a patient’s response to treatment[46].  A similar agent exists for PET imaging.  Incorporation of 
the positron emitter 18F as the 2’ group on glucose molecules yields 18Fluoro-deoxyglucose (18FDG), 
which can accumulate in tumors due to a tumor’s high glucose uptake and the inability for cells to 
metabolize FDG after uptake.  111In is also currently used as a diagnostic agent to measure tumor burden 
or metastasis by chelating it to an antibody targeted to an overexpressed tumor receptor[47].  The 
clinically used ProstaScint® is an 111In-conjugated monoclonal antibody against prostate specific 
membrane antigen used to diagnose prostate cancer.  In some cases, such as in the phase II clinical trial 
for a doxorubicin-linked polymeric micelle termed PK1, pharmacokinetics and biodistribution of the 
micelle were determined by conjugating the γ emitter 123I onto a small amount of PK1 analog during one 
treatment cycle[48].  The imaging analog contained an additional methacryloyltyrosinamide group 
whose tyrosine moiety was labeled with 123I via the Iodogen® labeling procedure[49].  These imaging 
strategies have laid the groundwork for those therapeutics that can simultaneously image and treat the 
tumor.   
1.6: Radioimmunotherapy 
Another recent effort has been placed on formulations that can accumulate in the tumor to 
provide diagnosis while simultaneously treating the tumor mass, and so far the most successful radio-
theranostics in the clinic seem to be those used in radioimmunotherapy (RIT).  RIT is a treatment 
strategy in which a therapeutic radioisotope such as 90Y or 177Lu is chelated and covalently bound to an 
antibody that will selectively target the tumor.  90Y has a higher β energy and a longer β range in tissue, 
while 177Lu decays via both β and γ emission, allowing SPECT imaging with simultaneous therapy.  The 
radioimmunotherapeutic Zevalin®, which uses 90Y, was the first in its class to receive FDA approval and is 
currently seeing success in the clinic[50].  Zevalin® is used against Non-Hodgkin’s Lymphoma (NHL) and 
uses the murine anti-CD20 antibody Ibritumomab against B-cells as a targeting and therapeutic agent.  
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Unfortunately, the antibodies used in this therapy are known to cause sometimes serious toxicity via 
complement activation and subsequent cytokine release[51-53].  Antibodies used in RIT are also very 
expensive, especially those that have been humanized or otherwise modified to reduce toxicity.   
An effective alternative to RIT may be to use a peptide instead of an antibody to target the 
chelated radionuclide to the tumor, which would be less toxic and less expensive.  This approach has 
been termed Peptide Receptor Radionuclide Therapy (PRRT) and the most successful designs have used 
a somatostatin analog called octreotate to target the somatostatin receptor overexpressed in 
neuroendocrine tumors[54-56].  The novel molecule DOTA-TATE (Figure 1.2) was generated by 
covalently linking the chelator DOTA to octreotate, allowing chelation of radionuclides such as 177Lu, 90Y, 
64Cu, and 111In for imaging and therapy.  PRRT with octreotate was recently approved by the FDA for use 
in patients with neuroendocrine cancer.  The dual therapy (β) and imaging (γ) capabilities of 177Lu allow 
simultaneous treatment and dosimetry of patients receiving 177Lu-DOTA-TATE[57].  The absorbed dose 
to healthy organs, especially the kidneys and bone marrow, was calculated from γ-scintigraphy and 
SPECT/CT images in order to provide the maximum therapeutic dose without exceeding the maximum 
acceptable dose to healthy tissue.   
1.7: SPECT Imaging with LCP 
The LCP formulation procedure allows efficient encapsulation of radiometals without the use of 
a chelator, and as of 2015, two articles have been published using LCP for SPECT imaging.  The first 
encapsulated the γ emitter 111In3+ into the core of LCP as an imaging agent to measure lymph node 
accumulation of LCP, initiating research on treating lymph node metastasis[26].  The second article, 
reproduced in Chapter 2 of this dissertation, encapsulated the γ and β emitter 177Lu3+ as both an imaging 
and therapeutic agent[25].  It was discovered that the 3+ charge on radiometals like 177Lu enabled very 
selective encapsulation in the LCP core, as their solubility product with phosphate are many orders of 
magnitude lower than that of calcium and phosphate (ksp lutetium-phosphate = 2x10-25; ksp calcium-
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phosphate = 1x10-7).  Consequently, when 177Lu was co-precipitated into the LCP core, a 70% 
encapsulation efficiency of 177Lu was maintained as the feed ratio of lutetium to calcium was increased 
by four orders of magnitude, allowing a tunable loading of radionuclide in a single-sized batch of LCP.  
Because only a trace amount of 177Lu is required to provide therapeutic effect, small-scale batches are 
still sufficient to produce 177Lu-LCP particles at human-level therapeutic dosing.  Even at the highest 
stable feed ratio of Lu:Ca, 177Lu-LCP maintains its encapsulation efficiency and morphology in particles 
that are still overwhelmingly composed of calcium phosphate (1:1000 Lu:Ca input ratio).  This eliminates 
the risk of heavy metal toxicity that would be presented in neutron-activatable theranostic 
nanoparticles, which can be loaded with as much as 20 wt% of the heavy metal ion[58].  In this case, the 
nanoparticles are bombarded with neutrons in a nuclear reactor to produce radioactive 166Ho from 
stable 165Ho.  Only a small fraction of the 165Ho is converted, increasing the dose of nanoparticles and 
heavy metal that must be given, but this method does decrease radioactive handling during fabrication. 
177Lu has a max β energy of ~500 keV and γ energies of 113 and 208 keV.  The γ energies are in 
the ideal range for efficient SPECT imaging and allow the biodistribution and tumor accumulation of 
177Lu-LCP to be measured using SPECT/CT (Figure 1.3A) and γ scintillation[25].  The therapeutic β 
emission from 177Lu-LCP was found to cause significant tumor inhibition via DNA damage-induced H2AX 
phosphorylation, followed by cellular apoptosis.  A change in the tumor microenvironment’s stromal 
structure was also detected, resulting in a decrease in fibroblast and collagen organization.  
Furthermore, the cytotoxic β emission from 177Lu also induced photons in the visible spectrum from the 
surrounding media.  This Cerenkov radiation is generated from the β electron moving faster than the 
speed of light in tissue and was detected using optical imaging in a live mouse (Figure 1.3B).  Although 
Cerenkov imaging does not provide a 3D reconstruction of biodistribution as SPECT does, it does allow 
less expensive and faster image acquisition that would be especially useful in determining early 
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biodistribution kinetics using multiple scans in quick succession.  Cerenkov radiation also allows imaging 
of other β-emitting nuclides such as 90Y that would otherwise not be available for imaging studies.   
1.8: Local Delivery of Radiation Therapy 
When delivered systemically, nanoparticle-based therapeutics are generally too large to clear 
from the body through the kidneys, and therefore tend to accumulate in the body’s other clearing 
organs, which are primarily the liver and spleen.  Splenocytes and the liver’s Kupffer cells will internalize 
these nanoparticles and attempt to metabolize the contents[59], so when delivering therapeutic siRNA 
or DNA, this off-target delivery is not of much consequence.  Additionally, since siRNA is generally 
chosen to knock down upregulated mRNA that is not abundant in healthy cells, and gene therapy often 
seeks to reintroduce a lost or downregulated gene that is present in healthy cells, off-target effects 
resulting from delivery to hepatocytes or other healthy cells are dampened.  In contrast, when radiation 
is delivered, the cytotoxic decay products can reach several millimeters away from the delivered source, 
indiscriminately acting on healthy and cancerous cells alike.  Although cancer cells are more susceptible 
to DNA damage due to their increased proliferation rate and decreased DNA repair capacity, care must 
be taken to minimize the dose to off-target organs.  Thus, current internal radiation therapies focus on 
local delivery of the radiation in order to increase the absorbed dose to the tumor and limit dose to 
healthy tissues. 
1.9: Brachytherapy  
Brachytherapy is a type of clinical radiotherapy in which the therapeutic radioactive source is 
permanently or temporarily placed in or near the tumor site.  The majority of brachytherapy procedures 
are performed in prostate cancer, and placement of the source(s) is pre-planned using transrectal 
ultrasound to maximize dose to the tumor while minimizing dose to healthy tissue, allowing safe dose 
escalation to nearly double that for external beam radiation therapy[60].  In high dose rate (HDR) 
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brachytherapy, sealed sources of Iridium-192 are temporarily placed within the prostate via 
intraperineal catheterization, while in low dose rate (LDR) brachytherapy, sealed radioactive seeds 
measuring ~0.8 mm x 4.5 mm are permanently deposited at precise intervals in the prostate.  The 
radioisotopes Cesium-131, Iodine-125, and Palladium-103 are preferred for LDR brachytherapy because 
their low-energy emissions provide rapid dose fall-off with increasing distance from the source, 
minimizing off-target dose[61].  To decrease incidence of seed movement or loss, each row of seeds can 
be sutured together to create a strand of several seeds[62].  LDR seeds are typically placed 1 cm 
apart[63], which allows a tunable dose to different areas of the prostate based on the activity 
encapsulated in each seed.   
The new concept of nanobrachytherapy is currently limited to simple intratumoral injection of 
radioactive nanoparticles[64], but there may be some value in delivering nanoparticles that can evenly 
diffuse within the tumor.  Major difficulties would be in reproducible dosimetry and clearance of the 
nanoparticles out of the tumor, as clearance would affect dosimetry as well as convey off-target toxicity 
to the clearing organ.  In order to control diffusion and minimize clearance, nanoparticle penetration 
through tissue could be tuned by modifying their charge and PEGylation density.  Highly loaded 177Lu-
LCP may be a good probe to quantify nanoparticle diffusion and clearance in the tumor, both by live 
animal imaging and in frozen tissue sections.  In its current formulation, LCP may be too acid-sensitive to 
ensure minimal clearance of the radioisotope over the initial decay of the delivered isotope, but a 
similar precipitate with a lower ksp such as Cu(PO4) may more effectively resist dissolution while 
maintaining the preferential encapsulation of trivalent radiometals.  Interestingly, excess cellular copper 
is known to generate reactive oxygen-dependent DNA damage, which could itself provide an effective 
combination therapy with the delivered radionuclide. 
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1.10: Selective Internal Radiation Therapy (SIRT) 
SIRT is another clinically approved local delivery method for internal radiation therapy.  This 
approach delivers radioactive microspheres loaded with 90Y to the liver via a surgically implanted 
catheter that is fed up the hepatic artery.  It is known that while the portal vein provides the majority of 
the blood supply to healthy hepatocytes in the liver, liver tumors are fed by the hepatic artery.  Thus, 
introduction of microspheres through the hepatic artery selectively target the tumor regions.  
Commercially available microsphere formulations such as Sir-Spheres by Sirtex are approximately 30 μm 
in diameter, which prevent cellular uptake and deep tumor penetration, but also help retain the 
microspheres around the tumor site while minimizing clearance through the hepatic capillaries.  SIRT is 
currently in several phase II and III clinical trials for use in combination with front-line 
chemotherapeutics against hepatocellular carcinoma (HCC) and advanced metastatic colorectal 
cancer[65, 66].    The data from recent clinical trials show that 90Y-SIRT + systemic chemotherapy 
provides significantly more hepatic progression-free survival than chemotherapy alone while 
maintaining tolerable liver and lung toxicity. 
Although local hepatic delivery using 90Y-microspheres for SIRT has shown success, there are 
areas in which it can be improved.  Most notably, the lack of tumor penetration by the microspheres 
requires a high-energy β emitter with a long depth of penetration to reach the deeper tumor tissue.  To 
maximize the absorbed dose to deep tumor cells, a large dose must be provided at the tumor periphery, 
which increases toxicity to healthy liver tissue.  A future 177Lu-LCP-SIRT therapy may be able to address 
these issues.  With a diameter of just 40-60 nm, the much smaller 177Lu-LCP could penetrate much 
deeper into the tumor mass, and the addition of an appropriate targeting ligand would allow selective 
uptake of the particles into the tumor cells themselves, bringing the radioactive payload closer to the 
target DNA in the cell nucleus.  The lower energy and shorter depth of penetration of 177Lu’s β emissions 
may then be adequate to treat the entire tumor at a lower total dose and with less toxicity to nearby 
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healthy tissue, although the efficacy of 177Lu as the encapsulated radionuclide should be compared with 
90Y.  If 177Lu-LCP is effective, the γ decay from 177Lu could then allow simultaneous confirmation of 177Lu-
LCP accumulation in the tumor mass via SPECT imaging.  Additionally, 177Lu-LCP could be easily co-
loaded with a phosphorylated chemotherapeutic for localized chemoradiation therapy.   
The much smaller size of LCP compared to Sir-Spheres also presents new challenges regarding 
the clearance of 177Lu away from the tumor site, not only from those particles that are injected into the 
hepatic artery and do not enter the tumor mass, but also from any radiation that initially enters the 
tumor and exits at a later time.  To ensure maximal tumor accumulation and minimal clearance of 177Lu-
LCP through the vena cava, simple changes to the surface of the particle should be made to encourage 
interaction with the tumor cell membrane and increase receptor-mediated endocytosis, such as 
modifying the outer leaflet with cationic lipids, lowering the surface PEG density, and adding a high 
affinity targeting ligand.  Peptide targeting ligands may be the most successful class of ligand for this 
purpose, as they generally bind with higher affinity than small molecule ligands, and are less bulky, 
expensive, and immunostimulatory than antibodies.  Peptide ligands against the α6β1 receptor 
overexpressed in human colon cancer cells may be successful against liver metastasis[67, 68], and 
similarly, overexpression of glypican-3 (GPC-3) in HCC has allowed synthesis and use of targeted 
peptides[69, 70].  Changes in the nanoparticle injection speed should also be considered, as a slower 
infusion of particles into the tumor will avoid saturation of the surrounding blood vessels and tumor cell 
receptors.  The introduction of novel nanodelivery approaches does indeed present new challenges in 
local delivery of radioisotopes, but the advantages posed by these new methods should make 
overcoming these challenges a worthwhile venture. 
1.11: Original Research: PET Imaging with LCP 
The successful encapsulation of 177Lu and 111In in the LCP core[25, 26] prompted experiments to 
encapsulate a radionuclide into an LCP formulation already containing chemotherapeutics in order to 
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better study its kinetics and biodistribution.  The LCP formulation that was chosen contained the 
cytotoxic nucleotide analog gemcitabine monophosphate, and had previously been published as a 
monotherapy and in combination with siRNA[16, 19, 20].  In previously unpublished experiments from 
this lab, trace 64Cu was encapsulated in the GMP-LCP core via co-precipitation and achieved a moderate 
encapsulation efficiency of ~50% because of its slightly lower solubility with phosphate when compared 
to calcium (a difference in Ksp of 3-4 orders of magnitude).  Using PET/CT, we were able to record a 
continuous dynamic scan documenting the first two hours after intravenous injection into mice 
(Supplementary Video S1), followed by additional time points at 16, 22, and 48 h after injection.  As 
shown in Figures 1.4 and 1.5A, tumor accumulation of 64Cu-GMP-LCP reached a maximum at t = 22 h and 
was clearly visible in the PET image.  Figure 1.5A shows that while max tumor uptake was sustained 
throughout the study, liver uptake peaked just 20 min after injection and showed a continuous decrease 
over time.  This time-dependent decrease in liver accumulation was not consistent with our experiments 
using 177Lu and 111In, in which liver accumulation of the probes remained high after 24 h. 
The difference in 177Lu/111In and 64Cu biodistribution is likely because of downstream action after 
the radionuclide cargoes are released from LCP via acid-sensitive dissolution in the cellular endosome.  
Because trivalent radiometals like 177Lu are not metabolically active, they are not actively excreted in the 
bile and intestines by the liver.  When free `177LuCl3 is injected intravenously, intestinal accumulation of 
177Lu is not observed[25].  In contrast, copper is a micronutrient that is actively metabolized in the liver, 
secreted into the bile, and excreted into the intestines[71].  Previously published time-dependent PET 
data of free 64CuCl2 injected intravenously shows high initial liver uptake, followed by a decrease in liver 
accumulation via washout through the intestines[72].  Figure 1.5C similarly shows that as 64Cu is 
excreted from the liver, the intestines begin to show 64Cu accumulation.  Because free 64Cu can only be 
excreted after release from LCP, this may suggest that LCP releases its payload within just a few hours of 
deposition.   
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Quick copper clearance from off-target organs can be desirable if one wants to decrease 
background signal or use copper itself as a theranostic agent[72], but when using 64Cu as a probe for 
nanoparticle biodistribution, it is important that 64Cu pharmacokinetics accurately represent those of 
the nanoparticle. Problematic copper metabolism after delivery can be remedied by chelating the 
copper to render it metabolically inactive.  For many years, the most effective copper chelators were the 
tetraazamacrocyclics DOTA and TETA, which admittedly had well-documented stability issues in vivo, 
allowing 64Cu to transchelate onto ceruloplasmin, the main copper-binding enzyme in the liver[73], [41].  
The chelator TE2A has shown better 64Cu stability than DOTA and TETA, allowing faster and more 
complete off-target clearance in vivo[74, 75], and recently, a class of bifunctional, bicyclic chelators 
called sarcophagines has shown excellent ability to stably chelate copper for tumor imaging[76, 77].  
Sarcophagines could potentially be covalently attached to the distal ends of PEG or outer leaflet lipids 
on nanoparticles in order to provide stable PET imaging.  To achieve reproducible results, chelator 
density on the nanoparticle must be optimized, excess chelators must be removed before addition of 
64Cu, and unincorporated 64Cu—if any—must be purified away before injection.  Alternatively, it may be 
possible to incorporate chelated 64Cu directly into the nanoparticle core.  A chelator that remains highly 
charged after 64Cu incorporation may co-precipitate with calcium phosphate in the LCP core, eliminating 
the need for surface chelation and accurately representing the biodistribution of the LCP core while also 
maintaining the metabolic inertness of the isotope.   
1.12: Future Directions: Magnetic Resonance Imaging (MRI) with LCP 
MRI uses the concept of nuclear magnetic resonance to reconstruct anatomical images.  By 
using a large magnet to manipulate the spin and magnetic moment of hydrogen atoms in the body, and 
then measuring their relaxation times, the distribution and structural characteristics of the hydrogen 
atoms can be measured[78].  MRI contrast agents such as iron oxide or gadolinium can themselves be 
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magnetized when under the influence of an external magnetic field, which shortens both the T1 and T2 
relaxation times of nearby hydrogen atoms[79].  Thus, to localize the contrast agents, the affected 
hydrogen atoms are measured, and not the contrast agents themselves.  This requires that a baseline 
reading be completed before adding the contrast agents. 
LCP has not yet been utilized in MRI for any purpose, but there are definitely some interesting 
theranostic applications for this imaging modality, since gadolinium is another trivalent cation that 
should be easily incorporated into the LCP core.  One advantage that MRI has over SPECT and PET is that 
it does not use radioactivity to generate an image, which makes formulation and optimization of a 
theranostic nanoparticle formulation safer and less expensive.  What functionally separates gadolinium 
and MRI from SPECT and PET imaging, however, is the fact that gadolinium must interact with the 
hydrogen atoms found mostly in water or tissue to generate its contrast, unlike radioisotopes that decay 
independent of their surroundings.  The magnetic moment generated by gadolinium on water decreases 
with distance to the sixth power, which means that gadolinium encapsulated in LCP and surrounded by 
calcium phosphate and lipid membrane will provide a much lower signal than free or released 
gadolinium.  Our previous experiments with 64Cu have provided some insight into the release profile of 
LCP in the liver, but using MRI to quantify gadolinium release from LCP could show relative release rates 
in all organs, determine if any release occurs in circulation, and measure whether the low pH of the 
tumor does indeed cause more rapid LCP dissolution.  This type of information would not be available if 
gadolinium were chelated to the outside of the particle, as it has been repeatedly shown that chelated 
gadolinium retains its ability to magnetize water[80, 81]. 
This approach can be taken one step further.  By encapsulating or chelating 64Cu to LCP as 
described above and also encapsulating gadolinium in the core, combined PET/MRI could be used to 
simultaneously measure the LCP biodistribution and release, showing which organ regions contain both 
released and unreleased LCP over time.  This type of information could provide insight into what kind of 
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dose the tumor and other organs are receiving, as faster release of a small molecule drug or siRNA from 
LCP should cause more acute toxicity than slow, sustained release. 
1.13: Optical Imaging: Use Caution 
Optical imaging generally uses fluorescent or luminescent contrast agents with emission 
spectrums in or near the visible light spectrum.  Fluorescent compounds require excitation by light 
before they are able to emit light of their own, while other luminescent compounds can utilize chemical 
reactions or biological processes to emit light without an incident excitation wavelength.  The wide 
range of available fluorescent probes and the low cost of optical imaging make fluorescent theranostics 
a very desirable modality for both in vitro and in vivo work, although attenuation and quenching in vivo 
can be problematic. 
A discussion on fluorescent theranostics has been conspicuously missing from this review, in 
part because of a recent article published by the Huang lab that has detailed several caveats when 
dealing with in vivo and ex vivo quantification of fluorescent signal[82].  Because of high tissue 
autofluorescence at lower wavelengths in the visible spectrum[83], red and near-infrared (NIR) probes 
are extensively used to quantify nanoparticle biodistribution.  In order to determine if these fluorescent 
probes accurately measure nanoparticle accumulation, the referenced article compared the 
biodistribution of LCP using three different quantification methods: Texas red oligonucleotide 
fluorescence, 3H-oligonucleotide β emission, and 111In γ emission.  For consistency, each contrast agent 
was loaded into the LCP core.  While the biodistributions of 3H and 111In agreed, the high amounts of 
blood in the liver, spleen, and other organs quenched and attenuated the fluorescent signal in those 
organs, inaccurately causing measurements of higher relative fluorescence in the tumor.  Even after 
perfusion to remove circulating blood from the liver, fluorescence quenching was not completely 
eliminated.  This phenomenon also occurred when using a near-infrared dye.  The quenching occurs at 
least in part because the secondary absorption peaks of hemoglobin and oxyhemoglobin present around 
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the red and NIR emission spectra absorb the light emitted from the fluorescent probes, effectively 
lowering their signals in blood-rich organs such as the liver.  Signal quenching could also occur because 
of greater tissue thickness of liver vs tumor, but the referenced article also compared tissue 
homogenates to show that equal amounts of different tissues will yield different fluorescence readings 
after adding equal concentrations of a fluorescent probe.  These results suggest that while comparing 
fluorescent signals in the same type of organ can provide qualitative results, comparing relative 
fluorescence across different organ types, especially when comparing blood-rich organs like the liver to 
sparsely vascularized tumors, is an inaccurate quantitative method and should not be used unless 
adequate standards and controls are generated. 
1.14: Conclusions 
The versatile LCP platform has proven itself to be a successful theranostic agent, and it is clear 
that there are many more future opportunities for LCP to combine simultaneous therapy and imaging in 
vivo.  Our lab has been primarily known as a formulation lab, but we have recently focused on 
innovating upon LCP in order to broaden therapeutic approaches and learn more about tumor biology.  
LCP’s success has not been based on changes in formulation as much as on innovative applications in 
cancer vaccine therapy, gene therapy, and theranostics that provide solutions in areas where 
therapeutic options are lacking.  In 2015, nearly 3,000 peer-reviewed articles were published in the field 
of cancer nanotechnology, and many had imaging or theranostic components to aid in tumor detection 
and treatment.  It is surely an exciting time in this field, as hundreds of minds collaborate against cancer, 
but as competition increases, the focus must not be on simply publishing novel papers, but on 
broadening our knowledge of cancer and improving treatment options for others.   
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Figure 1.1: Schematic of LCP nanoparticle synthesis.  LCP is capable of encapsulating siRNA, mRNA, 
DNA, phosphorylated peptides, nucleotide mimics, and radioactive isotopes in its calcium phosphate 
core.  Source: Adapted from Satterlee et al[25].  Copyright © 2015 Elsevier B.V.  License number: 
3815560646760 
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Figure 1.2: Chemical Structure of the PRRT agent 177Lu-DOTA-TATE 
 
 
 
 
177Lu
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Figure 1.3: SPECT and Cerenkov Imaging of 177Lu-LCP.  (A) SPECT/CT and (B) Cerenkov imaging of a live 
athymic nude mouse bearing a subcutaneous UMUC3/3T3 stroma-rich bladder cancer tumor at t = 24 
h after i.v. injection of 2.5 mCi of 177Lu-LCP.  Tumor accumulation of 177Lu is clearly visible above 
background, although not as high as liver and spleen accumulation.  SPECT and Cerenkov agree on the 
overall biodistribution of 177Lu.   Source: Adapted from Satterlee et al[25].  Copyright © 2015 Elsevier 
B.V.  License number: 3815560646760 
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Figure 1.4: PET Imaging of 64Cu-GMP-LCP. PET (left) and PET/CT (right) images of a live athymic nude 
mouse bearing a subcutaneous A549 lung cancer tumor.  Images show 2-D coronal sections at t = 22h 
after 64Cu-GMP-LCP administration.  Liver and tumor accumulation of 64Cu are both clearly visible.  
Dose of 64Cu = 500 μCi; dose of GMP = 5 mg/kg.   
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Figure 1.5: Biodistribution kinetics of 64Cu-GMP-LCP.  Biodistribution kinetics in a live athymic nude 
mouse bearing a subcutaneous A549 lung cancer tumor: (A) Quantification of 64Cu from 64Cu-GMP-LCP 
in liver and tumor, calculated from PET reconstruction ROIs; (B) PET images of 2-D transverse liver 
sections at different time points after injection; (C) PET images of 2-D coronal tumor sections at 
different time points after injection; (D) 3-D reconstruction of 64Cu biodistribution from 64Cu-GMP-LCP 
at different time points after injection.  Arrows at 16 h and 22 h time points show accumulation of 
64Cu in the intestines.  Dose of 64Cu = 500 μCi; dose of GMP = 5 mg/kg.   
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CHAPTER 2: CALCULATING TUMOR DOSIMETRY USING MIRD SCHEMA AFTER SYSTEMIC INJECTION 
OF 177LU-LCP 
 
2.1: Summary:  
Calculating tumor dosimetry allows measurement of absorbed doses of radiation to a tumor and 
may permit correlation of a certain dose to a given therapeutic effect.  The calculations presented in this 
chapter describe dosimetry for a subcutaneous tumor treated with 177Lu-LCP that has been administered 
intravenously.  Standard MIRD equations for absorbed dose were used to calculate the dose to the 
tumor over a period of 24 h, assuming that the activity in the tumor was all absorbed by the tumor and 
that no activity in other organs was absorbed by the tumor.  The tumor in question weighed 0.13g and 
was measured to contain 1.63 μCi of 177Lu upon dissection at t = 24h after injection of 177Lu-LCP.  The 
mean absorbed dose to the tumor over one day was calculated to be 0.91Gy. 
2.2: Introduction: 
A thorough discussion on nanoparticle-mediated internal radiation therapy must include an 
analysis of tumor dosimetry.  Dosimetry relates a given activity of delivered radiation—in units of 
Becquerels (Bq), or decays per second—to an amount of energy absorbed by the target tissue, described 
as the dose to the target.  The unit of absorbed energy, the Joule (J), can be normalized by dividing it by 
the mass of the target in kilograms (kg) to generate the unit of Gray (Gy), where 1 Gy = 1 J/kg.  Dose 
accumulates over time as decay products from the radioactive source, located either externally or 
internally, remain incident on the target.  In internal radiation therapy, wherein the source is located 
inside the body, decay products with short path lengths may deposit all of their energy within the source 
organ.  Decay products with longer path lengths, such as gamma rays or high energy electrons, may 
deposit a fraction of their energy into several organs at varying distances from the source.  The Medical 
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Internal Radiation Dose (MIRD) Committee has calculated tables for different nuclides describing the 
absorbed dose to target organs for a given activity present in a source organ.  For these MIRD 
calculations, it is assumed that the dose is homogeneously distributed in the source organ[84].  
2.3: Calculations 
The MIRD Committee has defined the mean absorbed dose (Dิ) to an organ as the integral of the 
dose rate (Ḋ) over time (t) (Eq.1), where the dose rate equals the accumulated activity (A) multiplied by 
the absorbed dose in the target tissue (T) per unit of activity in the source tissue (S), denoted as DF 
(TS) [84-88] (Eq.2).  The following calculations describe dosimetry for a subcutaneous tumor after 
intravenous injection of 177Lu-LCP.   Although 177Lu-LCP deposits heterogeneously in the tumor after 
systemic injection, these calculations quantify the average absorbed dose to the entire tumor. 
(1) Dഥ = ׬ Dሶ (t)dtஶ଴  
(2) Dሶ (ݐ) =  ܣ(ݐ) ∗ DF (TS)  
where: 
 Dഥ = ܩݕ =  ௃௢௨௟௘௦ (௃)
௞௚
 
 Dሶ = ௃
௦௘௖௢௡ௗ (௦)
 
 ܣ = ܤ݁ܿݍݑ݁ݎ݈݁ (ܤݍ) = ௗ௘௖௔௬௦
௦
 
 DF (TS) = ீ௬
஻௤∗௦
 
The nuclide used for these calculations was 177Lu, which has a mean energy from beta particles, 
conversion electrons, and Auger electrons of 147 keV [88].  For this analysis, the absorbed dose from 
gamma photons released by 177Lu was not considered.  The average length of the beta particles in tissue 
is only 200-300 μm [89], so for these calculations it was assumed that all activity in the source organ 
(tumor) was also absorbed in the tumor, which was also the target organ in this scenario.  Although 
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there is technically a small amount of activity on the outer edge of the tumor that is absorbed in other 
organs (i.e. skin in a subcutaneous model), there is also a small amount of activity in these other organs 
that is absorbed by the tumor edge.  This favors the assumption that only the activity of 177Lu in the 
tumor needs to be considered to approximate tumor dosimetry.  If a higher energy beta emitter with a 
longer beta path length such as 90Y were used here, this assumption would be much less accurate. 
Given this assumption, a given activity accumulated in a tumor can be converted to a dose rate 
according to Eq 3: 
(3) 1 ݉݅ܿݎ݋ܿݑݎ݅݁ (ߤܥ݅) = 37000 ܤݍ = ଷ଻଴଴଴ ௗ௘௖௔௬
௦
∗ ଴.ଵସ଻ெ௘௏
ௗ௘௖௔௬
= ହସଷଽெ௘௏
௦
∗ ଵ.଺ாିଵଷ
ெ௘௏
= ଼.଻ாିଵ଴
௦
 
The dose rate in the tumor may change over time for many reasons.  Two of these reasons were 
accounted for in these calculations: 
(a) Tumor dose rate will decrease over time due to radioactive decay.  177Lu t1/2 = 6.71 days = 
42156s.  Activity at time t can be calculated according to Eq 4: 
(4) ܣ௧ = ܣ଴݁ିఊ௧ ,   where ߛ =
௟௡(ଶ)
௧భ
మൗ
 
  Therefore, for 1 μCi of 177Lu, Dt can be calculated as (Eq 5): 
         (5)   ܦ௧ = 8.7ܧ − 10 ∗ ݁ିଵ.ଶாି଺∗௧ ,   where units of t are seconds 
The tumor studied for these calculations was a subcutaneously inoculated UMUC3/3T3 
tumor that was measured to weigh 0.13 grams and contain 1.63 μCi of activity when it was 
dissected from a mouse at t = 24 h after injection of 177Lu-LCP.  The dose to this tumor with 
respect to decay at time t is therefore:  
         (6)   Dሶ (ݐ)  = 1.6ܧ − 9 ∗ ݁ିଵ.ଶாି଺∗௧ 
(b) The tumor accumulation and pharmacokinetics of systemically injected 177Lu-LCP affect dose 
rate because at early times after injection, much of the activity is still in circulation.  Just 
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after injection, the tumor begins accumulating nanoparticles and therefore activity.  By 
measuring 177Lu-LCP circulation pharmacokinetics, the percentage of injected nanoparticles 
still in circulation as a function of time was determined.  In order to estimate the amount of 
activity within the tumor at 0 < t < 24 h, it was assumed that the tumor accumulation was 
proportional to the fraction of the injected dose that had left circulation at that time, with 
the maximum tumor accumulation occurring at t = 24h.  177Lu-LCP was formulated with 
DOTAP in the outer leaflet in order to decrease circulation time, and PK was calculated in n = 
5 mice, shown in Table 2.1 and Figure 2.1. 
      Two equations were then calculated to model the two distinct phases of 177Lu-LCP PK: 
(7) For 0 < t < 1800s, ݕ = 0.0045ݐ 
(8) For 1801 < t < 86400s, ݕ = 0.05 ln(ݐ) + 0.41 
 
By applying 177Lu-LCP PK to the radioactive decay equation, one overall dose rate curve was 
generated (Fig 2.2).  Two separate equations were used to describe the dose rate: 
(9) For 0 < t < 1800s, Dሶ (ݐ) = 7ܧ − 13 ∗ ݐ  
(10) For 1801 < t < 86400s, a high order polynomial was used to best model the curve: 
Dሶ (ݐ) = 3.2E − 34 ∗ ݐହ − 9.4ܧ − 29 ∗ ݐସ + 1.1ܧ − 23 ∗ ݐଷ − 6.4ܧ − 19 ∗ ݐଶ + 1.9ܧ −
14 ∗ ݐ + 1.1ܧ − 9   
 
Integrating Dሶ (ݐ) from t = 0 to 86400s (1 day) yields a mean absorbed dose of Dഥ = 0.000119ܬ.  
Dividing by the weight of the tumor in kg (weight = 0.00013 kg) yields a dose of 0.91 Gy over one day.  
The calculations used to arrive at this value also return the same values reported in a similar MIRD 
dosimetry model of tumor accumulation of 177Lu in PRRT [88].   
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2.4: Conclusions: 
The MIRD calculations for mean absorbed dose over one day yield a dose of 0.91Gy from 177Lu 
delivered to a tumor via systemic injection of 177Lu-LCP.  The accumulated activity in this UMUC3/3T3 
tumor is similar to the activity in the UMUC3/3T3 tumors described in the biodistribution data for 177Lu-
LCP provided in Figure 3.4B.  As shown in Figure 3.8A, 177Lu-LCP causes significant tumor growth 
inhibition, suggesting that the cumulative absorbed dose across the first day and subsequent days after 
treatment is sufficient to induce therapeutic effect.   
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Table 2.1: 177Lu-LCP Pharmacokinetics.  177Lu-LCP was administered i.v. at t = 0, and at each time 
point, a small amount of blood was removed from the tail vein.  The mass and activity of each sample 
was quantified at the time of acquisition.  n = 5.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t (h) t (s) Fraction out of Circ.
0 0 0
0.5 1800 0.80
1 3600 0.82
2 7200 0.85
4 14400 0.87
8 28800 0.93
24 86400 1.00
177Lu-LCP Pharmacokinetics
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Figure 2.1: 177Lu-LCP Pharmacokinetics.  Graphical representation of 177Lu PK shown in Table A1.  The 
fast distribution phase is modeled by a linear equation (Eq 7) and the slower elimination phase is 
modeled by a logarithmic equation (Eq 8). 
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Figure 2.2: Overall dose rate for 177Lu-LCP.  Graphical representation of overall dose rate.  To achieve 
the best fit, two trend lines were generated.  The initial linear equation modeled dose from 0 < t < 
1800s, and a high order polynomial modeled  1800 < t < 86400s with an R2 value of 0.999. 
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CHAPTER 3: A RADIO-THERANOSTIC NANOPARTICLE WITH HIGH SPECIFIC DRUG LOADING FOR 
CANCER THERAPY AND IMAGING2 
 
3.1: Summary 
We have developed a theranostic nanoparticle delivering the model radionuclide 177Lu based on 
the versatile lipid-calcium-phosphate (LCP) nanoparticle delivery platform. Characterization of 177Lu-LCP 
has shown that radionuclide loading can be increased by several orders of magnitude without affecting 
the encapsulation efficiency or the morphology of 177Lu-LCP, allowing consistency during fabrication and 
overcoming scale-up barriers typical of nanotherapeutics.  The choice of 177Lu as a model radionuclide 
has allowed in vivo anticancer therapy in addition to radiographic imaging via the dual decay modes of 
177Lu.  Tumor accumulation of 177Lu-LCP was measured using both SPECT and Cerenkov imaging 
modalities in live mice, and treatment with just one dose of 177Lu-LCP showed significant in vivo tumor 
inhibition in two subcutaneous xenograft tumor models.  Microenvironment and cytotoxicity studies 
suggest that 177Lu-LCP inhibits tumor growth by causing apoptotic cell death via double-stranded DNA 
breaks while causing a remodeling of the tumor microenvironment to a more disordered and less 
malignant phenotype.   
 
 
                                                          
2 This chapter originally appeared as a research article in the Journal of Controlled Release.  The original citation is 
as follows: Satterlee A, Yuan H, and Huang L.  A radio-theranostic nanoparticle with high specific drug loading for 
cancer therapy and imaging.  Journal of Controlled Release. 2015; 217: 170-182.  
http://dx.doi.org/10.1016/j.jconrel.2015.08.048 
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3.2: Introduction: 
Standard cancer treatment regimens use combinations of surgery, chemotherapy, and radiation 
therapy to eradicate the disease.  The majority of patients receiving radiation treatments undergo 
external beam radiation therapy, but systemic internal radiotherapy has also achieved substantial 
clinical success in the last decade [90].  Unlike external beam therapy, which generally bombards the 
tumor area with photons or electrons emitted from an external source, systemic radiotherapy targets 
radionuclides to the tumor site via intravenous injection.  The radiation source therefore resides inside 
the body, and the low radiation emission distance only allows the therapy to affect cells positioned close 
to particle deposition.  This is in contrast to external beam therapy in which x-rays or gamma rays pass 
through the body from an external source.  The current gold standard in systemic radiotherapy, called 
radioimmunotherapy, chelates the radioisotope to a tumor-targeted monoclonal antibody.  The radio-
immunotherapeutic Zevalin, which is labeled with the radioisotope 90Yttrium, was the first of its kind, 
approved by the FDA in 2002 for use against B-cell lymphoma [50], but its clinical success has been 
tempered because of its high cost and antibody-mediated toxicity [51-53].   
In this paper we describe a novel method for systemic internal radiotherapy.   We have 
previously developed a targeted and versatile nanoparticle platform termed Lipid Calcium Phosphate 
(LCP) [8].  LCP is formulated by mixing two reverse microemulsions containing concentrated calcium and 
phosphate, and can encapsulate phosphorylated small molecules, peptides, and nucleic acids through 
their co-precipitation into the amorphous calcium-phosphate precipitate [19, 20, 23].  In this report we 
have now extended the application of this LCP platform by developing a theranostic nanoparticle with 
high specific drug loading for cancer therapy via the encapsulation of the model radioisotope 
177Lutetium (177Lu).  Trivalent cations such as lutetium can be driven into LCP, as their solubilities with 
phosphate are many orders of magnitude lower than the solubility of calcium phosphate.  Phosphate 
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then prefers to precipitate with these radioisotopes and even a trace amount can be encapsulated with 
high efficiency.  
High encapsulation efficiency of a drug is often attainable only when a low amount of drug is 
loaded into each particle, requiring large doses of the particle to achieve a therapeutic effect.  This can 
cause particle-mediated toxicity and make clinical scale-up very difficult and expensive.  Our method of 
radioisotope loading does not encounter these issues.  Because 177Lu can be driven into LCP due to its 
low solubility with phosphate, and because only a small mass of 177Lu is needed to provide a therapeutic 
effect, the drug loading window for a batch of LCP can span several orders of magnitude without 
affecting the 177Lu encapsulation efficiency or LCP morphology, and without requiring a change in any 
other input parameters.   
177Lu was chosen as a model radionuclide because of its ability to provide simultaneous imaging 
and therapy: γ-radiation from 177Lu is detectible using Single Photon Emission Computed Tomography 
(SPECT), while β-decay from 177Lu causes DNA damage to nearby cells in addition to inducing Cerenkov 
radiation that is detectible using optical imaging techniques.  Targeted delivery of these radionuclides 
therefore allows measurement of tumor accumulation in live mice while simultaneously treating the 
tumor mass.  Unlike chemotherapeutics, radioisotopes like 177Lu decay at a constant rate independent of 
their environment, providing a low, continuous dose to the tumor consistent with their decay rate.  We 
therefore tested the ability of 177Lu-LCP to achieve a sustained and quantifiable therapeutic effect in vivo 
after just a single dose. 
3.3: Materials and Methods: 
 
3.3.1: Materials 
  177LuCl3 was purchased from PerkinElmer (Waltham, MA).  1,2-dioleoyl-sn-glycero-3-phosphate 
(DOPA), and  1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were purchased from Avanti Polar Lipids 
(Alabaster, AL).  N-(Carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3-
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phosphoethanolamine, sodium salt (DSPE-PEG2000) was purchased by NOF America Corporation (White 
Plains, NY).  DSPE-PEG2000-Anisamide (DSPE-PEG-AA) was synthesized in our lab as described previously 
[91].  Other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
3.3.2: Cell Lines 
Three different cell lines were used in the experiments described below: NCI-H460 (H460) 
human non-small cell lung cancer cells, UMUC3 human bladder cancer cells, and NIH/3T3 (3T3) murine 
fibroblasts.  In some experiments, 3T3 cells that had been stably transfected with green fluorescent 
protein (GFP) were used. 
3.3.3: Experimental Animals 
6-8 week old female athymic nude mice were used for all experiments presented in this 
manuscript.  These mice were purchased from the National Cancer Institute (Bethesda, MD) and bred at 
the Division of Laboratory Animal Medicine at the University of North Carolina-Chapel Hill.  All work 
performed on these animals was approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina-Chapel Hill. 
3.3.4: 177Lu-LCP Fabrication and Characterization 
177Lu-LCP fabrication has been modified [8, 26] from what is described in previous publications.  
Two reverse microemulsions were prepared in round-bottom flasks.  Both microemulsion oil phases 
contained 73.7:6.7:9.7:10 Cyclohexane:Hexanol:IgepalCO520:TritonX-100 (v:v:v:v).  25mg/ml DOPA was 
added in chloroform to one oil phase (1:0.023 oil:DOPA v:v).  A Phosphate aqueous phase (1:0.0125 
oil:aqueous v:v) containing 100mM Na2HPO4 in 0.0125M NaOH was added to the DOPA oil phase with 
stirring.  A Calcium aqueous phase containing 500mM CaCl2 and trace 177LuCl3 in 0.0125M HCl was added 
to the other oil phase.  After five minutes, the oil phase containing phosphate was added to the oil 
phase containing calcium and stirred for 40 minutes.  100% ethanol was then added to oil (1:1 
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ethanol:oil v:v) and stirred for 30 minutes.  LCP was washed three times via centrifugation at 12,600g, 
removing the supernatant, replacing the supernatant with 100% ethanol, and vortexing the solution to 
resuspend the LCP pellet.  Lu, Ca, and PO4 that had not precipitated during mixing were discarded in the 
supernatant of the initial wash (~15% of input 177Lu was removed here), and minimal 177Lu signal was 
detected in the second and third supernatants.  After the final wash, the precipitate was dissolved in 
chloroform and centrifuged at 10,000g for five minutes.  This supernatant then contained the organic-
soluble LCP cores, and the pellet contained any precipitate that was not well-coated in DOPA, and 
therefore not soluble in chloroform (~15% of input 177Lu was removed here).  Purifying the LCP cores in 
these two ways ensured that 177Lu was only present inside the LCP.  Outer leaflet lipids (OLLs) dissolved 
in chloroform were then added to the chloroform-soluble cores (40:40:18:2 DOPC:cholesterol:DSPE-
PEG2000:DSPE-PEG2000-AA mol:mol:mol) (0.11:1 total OLL:initial oil phase v:v; all lipids at 20mM 
concentration).  In experiments using DiI-labeled LCP, DiI dissolved in chloroform was added to the cores 
with the OLLs (1:100 DiI:total OLL mol:mol).  Chloroform was evaporated until the particles and lipids 
coated the vial in a lipid film.  Particles were then rehydrated with 80oC water to the injection volume.  
The solution was vortexed and sonicated liberally, then heated at 80oC for >10 min and passively cooled.  
The anisamide ligand was used in all formulations to target the sigma receptor overexpressed in UMUC3 
and H460 cells [16, 92]. 
In experiments using DiI-labeled Lu-LCP, sucrose gradient ultracentrifugation (50,000g for 4 h) 
was used to purify DiI-Lu-LCP from excess free DiI and DiI that had incorporated into excess free 
liposomes.   
Encapsulation efficiency of 177Lu into 177Lu-LCP was measured by a Model AA2010 “Nucleus” 
Gamma Scintillation Counter or a Capintec Radioisotope Calibrator CRC-127R and calculated as (signal 
from 177Lu in LCP cores)/(signal from 177Lu in input aqueous phase).  177Lu-LCP hydrodynamic diameter 
and zeta potential were measured after sucrose gradient ultracentrifugation using a Malvern Nano ZS 
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dynamic light scattering instrument.  Three different batches of LCP were measured.  Particle size was 
corroborated using transmission electron microscopy (TEM). 
3.3.5: Loading Capacity 
To simulate an increase in 177Lu loading into 177Lu-LCP, a trace amount of 177Lu was 
supplemented with additional nonradioactive 175Lu.  As the Lu:Ca input ratio was increased from 
1:10,000,000 to 1:1, no changes in any inputs were made save for the increase in 175Lu.  177Lu EE was 
measured using gamma scintillation and 177Lu-LCP morphologies/structural makeups were measured 
using TEM and energy-dispersive X-ray spectroscopy (EDS) at the Chapel Hill Analytical and 
Nanofabrication Laboratory at the University of North Carolina at Chapel Hill.  TEM images were taken 
using a TEM JEOL 2010F-FasTEM or a TEM JEOL 100CX II, and EDS measurements were taken using the 
TEM JEOL 100CX II. 
3.3.6: Pharmacokinetics and Biodistribution 
Healthy nude mice were injected with 177Lu-LCP or free 177LuCl3 of known activities.  The 177Lu-
LCP or 177LuCl3 was injected into the left tail vein and circulating 177Lu-LCP or 177LuCl3 was measured by 
removing 20-30 µl of blood from the right tail vein at several time points after injection.  The signal was 
read using gamma scintillation and was used to calculate the total signal remaining in the blood.  A 
Microsoft Excel Add-In called PKSolver [93] was used for the pharmacokinetic analysis.  In a separate 
experiment, H460 or UMUC3/3T3 tumor-bearing mice were injected with a therapeutic dose of 177Lu-
LCP or free 177LuCl3.  Twenty four h after injection, the mice were sacrificed and their organs were 
dissected and read for 177Lu activity.   
3.3.7: SPECT and Cerenkov Imaging 
UMUC3/3T3 tumor-bearing nude mice were i.v. injected with 2.5 mCi of 177Lu-LCP or free 
177LuCl3.  Twenty four h later, the mice were imaged using a small animal SPECT/CT system (eXplore 
38 
 
speCZT, GE Healthcare) at the Small Animal Imaging facility on the UNC campus.  SPECT Images were 
taken with the energy window to be set from 188-229 keV to receive the main gamma photon from Lu-
77 peaked at 208 keV.  A mouse slit collimator was used to provide whole body imaging with 1.5mm 
transaxial and 2.5mm axial resolution, and a pinhole collimator was used for partial body imaging with 
higher resolution (1mm isotropic resolution).  Immediately after SPECT/CT imaging, the mice were taken 
to an in vivo optical imaging system (IVIS-Kinetic, Perkin Elmer) to measure Cerenkov emissions 
generated by 177Lu.   
3.3.8: In Vivo Tumor Inhibition 
Six to eight week old nude mice were subcutaneously inoculated with 100ul PBS containing 
5x106 H460 cells or 5x106 UMUC3 cells + 2.5x106 3T3 cells in 25% matrigel (BD matrigel matrix high 
concentration) on the left flank.  After 8-12 days, when tumors had reached a size of 100-150mm3, mice 
were given a single injection of PBS (Untreated mice), non-radioactive (cold) 175Lu-LCP, free radioactive 
177LuCl3, or radioactive 177Lu-LCP.  Mice bearing UMUC3/3T3 tumors received a dose of 200 µCi/mouse 
and mice bearing H460 tumors received a dose of 250 µCi/mouse.  Mouse weight was measured every 2 
days until untreated mice reached humane endpoints.  Tumor volume was measured with digital 
calipers and calculated as (L x W x D)/2.  n = 5-8.  Student’s t-test of the final AUC used for statistical 
analysis. 
3.3.9 Tumor Accumulation  
Nude mice bearing s.c. H460 or UMUC3/3T3 tumors were treated with one dose of 250 µCi or 
200 µCi 177Lu-LCP, respectively, or appropriate controls.  The lipid bilayer of the 177Lu-LCP particles were 
labeled with the fluorescent small molecule DiI to allow LCP measurement in the tumor.  Twenty four h 
after injection, mice were sacrificed and tumors were dissected and cut in half.  One half was frozen in 
OCT, sectioned, and mounted for DiI Lu-LCP imaging, and the other half was fixed in 4% formalin, 
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embedded in paraffin, and sectioned for CD-31 staining (1:100 dilution rabbit primary Ab, Abcam 
#ab28364; 1:100 dilution anti-rabbit 647 fluorescent secondary Ab, Cell Signaling #4414) and DAPI 
counterstain. 
3.3.10 Cytotoxicity Studies 
One, 2, and 4 days after treatment with 200 µCi 177Lu-LCP or controls, UMUC3/3T3 tumor-
bearing nude mice were sacrificed and their tumors were dissected, fixed, and sectioned in paraffin.  
Adjacent sections were stained for p-H2AX immunofluorescence (1:100 dilution Rabbit monoclonal 
primary Ab, Cell Signaling #9718; 1:100 dilution anti-rabbit 647 fluorescent secondary Ab, Cell Signaling 
#4414) and Terminal deoxynucleotidyl transferase dUTP nick end labeling (DeadEndTM Fluorometric  
TUNEL System, Promega) with DAPI counterstains.   
3.3.11 Microenvironment Studies 
Nude mice were inoculated with UMUC3/3T3-GFP (fluorescent) tumors using the same cell 
numbers reported above.  When tumors reached ~400 mm3, mice were treated with 200 µCi of 
fluorescently labeled DiI-177Lu-LCP or controls.  After 2 days, mice were sacrificed and their tumors were 
dissected and prepared for freezing in OCT via a 2-h fixation in 4% formalin followed by overnight 
incubation in a 30% sucrose solution at 4oC.  The frozen tumors were sectioned and imaged with DAPI 
counterstain to measure GFP and DiI distribution.  DiI distribution was quantified using Matlab. 
Separate nude mice were inoculated with UMUC3/3T3 (nonfluorescent) tumors.  When tumors 
reached ~300 mm3, mice were treated with 200 µCi of 177Lu-LCP or controls.  Four days after treatment, 
the tumors were dissected, fixed, and sectioned in paraffin.  Adjacent sections were trichrome stained 
and stained for alpha-smooth muscle actin (α-SMA) immunofluorescence (1:100 dilution Rabbit 
monoclonal primary Ab, Abcam #ab5694; 1:100 dilution anti-rabbit 647 fluorescent secondary Ab, Cell 
Signaling #4414) with DAPI counterstain.  The stained sections were digitally scanned using the Aperio 
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Scanscope at the University of North Carolina-Chapel Hill’s Translational Pathology Lab.  Quantitative 
analysis was performed on Imagescope and ImageJ software.   
3.3.12: Toxicity Studies 
Nude mice and CD-1 mice were treated with 250 µCi of 177Lu-LCP or appropriate controls and 
were sacrificed 12 days after treatment.  Blood and organs were dissected.  Serum levels of AST, ALT, 
BUN, and creatinine were measured, and organs were stained with H&E to measure any changes in 
tissue morphology.  Whole blood was measured for changes in white blood cell count (WBC), hematocrit 
(HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin count (HGB), and platelet count 
(PLT).    
3.4: Results:  
 
3.4.1: Lu-LCP Fabrication and Characterization 
The LCP nanoparticle platform preferentially encapsulates 177Lu in its solid amorphous calcium 
phosphate core during fabrication (Scheme shown in Figure 3.1A).  Just a trace amount of 177Lu can be 
efficiently encapsulated because of lutetium’s much lower solubility with phosphate (ksp = 2x10-25) [94] 
when compared to calcium’s solubility with phosphate (ksp = 1x10-7).  The fabrication protocol for 177Lu-
LCP was modified [8, 26] from previous publications to maximize 177Lu encapsulation efficiency (EE) at 
approximately 70%, with the majority of the loss occurring during washing and purification.  Particles 
were measured via dynamic light scattering to have a diameter of 36 ± 9 nm and a polydispersity index 
of 0.27 ± 0.05, with a zeta potential of -6.7 ± 3.5 mV after separating the particles from excess empty 
liposomes using sucrose gradient centrifugation (Table 3.1).  Particle size was corroborated by 
transmission electron microscopy (Figure 3.1B-C).  Although cellular entry is not requisite for 177Lu-LCP 
to achieve therapeutic effect, because anisamide has been proven as an effective targeting ligand 
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against the sigma receptor overexpressed in epithelial cancers such as UMUC3 and H460 [16, 92], and 
because receptor-mediated endocytosis draws nanoparticles inside the cell and closer to nuclear DNA, 
DSPE-PEG-Anisamide was exclusively used in all Lu-LCP formulations as described in section 3.1 to 
provide the greatest statistical chance for treatment efficacy. 
3.4.2: Loading Capacity 
Preferential loading of 177Lu allows 177Lu-LCP to be fabricated with a very high radioisotope 
concentration, consequently allowing very high drug loading in a particle that is still overwhelmingly 
comprised of calcium phosphate.  Figure 3.2 and Table 3.2 show that the drug loading window in 
equivalent-sized batches of LCP core spans across several orders of magnitude without affecting the 
177Lu encapsulation efficiency and not requiring a change in any other input parameters.  Additionally, 
the LCP morphology remains unchanged up to a Lu:Ca input ratio of 1:1000 (Figure 3.3A-F), above which 
the Lu starts becoming a structural component of the LCP, as measured by EDS (Figure 3.3G), which 
introduces heterogeneity to the formulation.  As Lu:Ca is increased to 1:1, Lu forces out nearly all Ca 
from the LCP to form cores of LuPO4, but the total dose of heavy metal per particle is undesirable due to 
its inherent toxicity.  These data suggest that the maximum Lu:Ca input ratio that maintains desirable 
encapsulation and morphology is 1:1000.  At this input ratio, ~24 mCi of 177Lu—enough to treat over 100 
mice—can be encapsulated in a batch size of only 3.2 total mL of oil phase.  Considering that it is not 
uncommon for other types of LCP formulations to be synthesized in batches of 120ml or more for small 
mouse studies, one can understand how Lu-LCP is able to avoid scale-up complications generally 
associated with nanoparticles.  Moreover, a very small mass of total lutetium—approximately 70 
pmol/mouse, or 6x10-4 mg/kg—is used here to achieve therapeutic effect.  This low total dose is 
important in minimizing heavy metal-mediated toxicity.  Combined, the high drug loading window and 
low total mass of lutetium in 177Lu-LCP minimize batch size and toxicity while subsequently allowing the 
treatment of a large number of animals per batch.   
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3.4.3: Pharmacokinetics and Biodistribution 
The pharmacokinetics and biodistribution of 177Lu-LCP were determined in tumor-bearing nude 
mice.  A two-compartment model [93] was used to calculate the clearance half-lives, which were 0.52 h 
for the distribution half-life, t1/2α, and 7.28 h for the elimination half-life, t1/2β, as shown in Figure 3.4A.  
Pharmacokinetic analysis was also performed for free 177LuCl3, which showed nearly 80% blood 
clearance in the first 30 min after injection (Figure 3.5).  It can therefore be concluded that the 
circulating signal from mice given 177Lu-LCP is indeed from intact particles.  The biodistribution of 177Lu-
LCP and free 177Lu in tumor-bearing mice is given in Figure 3.4B.  177Lu-LCP shows significant 
accumulation in the tumor, as well as accumulation in the nanoparticle clearing organs, the liver and 
spleen, as it is too large to clear renally.  In contrast, free 177Lu is an ion that is plenty small to clear 
through the kidneys, but also selectively accumulates in the bones, as lanthanide elements are known to 
do [95].  Free 177Lu also shows some kidney accumulation, which may occur during the quick renal 
clearance of the element (Figure 3.4B).   
3.4.4: SPECT and Cerenkov Imaging 
In addition to allowing simple means of detection using gamma scintillation, 177Lu can also be 
used as a SPECT contrast agent, permitting measurement of 177Lu biodistribution and tumor 
accumulation in live mice.  Figure 3.6A-E shows the biodistribution of 177Lu-LCP 24 h after injection, 
including the visible accumulation of 177Lu in the tumor.  In contrast, free 177LuCl3 does not accumulate in 
the tumor and therefore tumor accumulation is not visible using SPECT/CT imaging (Figure 3.6F-H).   
Interestingly, 177Lu also allows imaging via its β-emissions, which are the same decay products 
(electrons) that induce its therapeutic effect.  As the β-particles move through the tissue over their 
average path length of ~250 μm, they induce photon emissions from the medium with energies in the 
visible spectrum.  This so-called Cerenkov light was measured using an in vivo optical imaging system 
(Figure 3.7), also showing tumor uptake of 177Lu-LCP and corroborating the results obtained during 
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SPECT/CT imaging.  Cerenkov imaging is a particularly interesting imaging modality because it offers a 
less expensive and more convenient alternative to SPECT that is not generally used in this field.  
Although its spatial resolution and depth of penetration is not as high as SPECT or PET, Cerenkov 
imaging uses less expensive hardware and requires acquisition times of only a few seconds, if the 
radioisotope and dose are adequate.   
3.4.5: In Vivo Tumor Growth Inhibition 
To assess the effectiveness of a single treatment of 177Lu, one dose of 177Lu-LCP was 
intravenously injected into two different subcutaneous xenograft tumor models.  One of the models was 
an aggressive stroma-rich human bladder cancer model previously developed by our lab.  This model 
uses both UMUC3 bladder cancer cells and NIH-3T3 fibroblasts to generate a tumor that has been 
shown to be more similar to patient bladder cancer than UMUC3 tumors alone [15].  As shown in Figure 
3.8A, a single 200 µCi dose of 177Lu-LCP showed sustained and significant tumor growth inhibition 
compared to tumors treated with nonradioactive 175Lu-LCP and tumors receiving only free 177LuCl3.  
177Lu-LCP was also tested on the aggressive and radio-resistant [96] H460 human non-small cell lung 
cancer model; an increased dose of 250 µCi of 177Lu-LCP provided statistically significant tumor growth 
inhibition as shown in Figure 3.8B.  This boosted dose was still low enough to avoid changes in mouse 
body weight (Figure 3.9), and the accumulated dose over the course of the study did not significantly 
elevate liver/kidney toxicity markers (Table 3.3). 
3.4.6: Tumor Accumulation 
To compare the localization of 177Lu-LCP inside H460 and UMUC3/3T3 tumors, the fluorescent 
small molecule DiI was incorporated into the outer leaflet of the nanoparticle.  DiI has been widely used 
in liposomal formulations and as a cell membrane marker, and is well known to faithfully remain in the 
hydrophobic portion of the lipid bilayer [28, 97].  Tumor-bearing mice were sacrificed 24h after injection 
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with DiI-labeled 177Lu-LCP, and tumor sections were imaged for DiI uptake.  Figure 3.10A shows that the 
bladder cancer tumor has more homogeneous uptake of particles when compared to the H460 lung 
cancer tumor.  This could be because the bladder cancer tumors contain more CD-31-positive area than 
the H460 tumors (Figure 3.10B), corresponding to more vasculature.  This could also explain the greater 
tumor accumulation of 177Lu-LCP in the UMUC3/3T3 tumors shown in Figure 3.4B.  The UMUC3/3T3 
bladder cancer tumor model was therefore chosen for more detailed mechanistic analysis.  
3.4.7: Mechanisms of Tumor Growth Inhibition: Cytotoxicity Studies 
While many chemotherapeutic therapies and treatments using external radiation require 
multiple doses to generate therapeutic effect, just one dose of 177Lu-LCP provides continuous treatment 
of the tumor as the 177Lu slowly decays, leading to sustained tumor growth inhibition for several days.  
We desired to investigate the mechanisms by which this sustained effect occurs, and hypothesized that 
the cytotoxic β-emissions from 177Lu would persistently induce double-stranded DNA breaks.  To study 
this phenomenon, we looked further into the stroma-rich bladder cancer tumor model.  Mice were 
sacrificed one, two, and four days after treatment with 200 µCi of 177Lu-LCP or appropriate controls.  
Immunofluorescent staining for p-H2AX, a protein that is phosphorylated in response to DNA double-
stranded breaks [98], showed that the maximum induction of the protein occurred two days after 
treatment and remained elevated even four days after treatment (Figure 3.11A).  This DNA damage led 
to cell death via apoptotic fragmentation of DNA, which was most induced four days after treatment as 
measured through the TUNEL assay (Figure 3.11B). This suggests that the cumulative dose of radiation 
from 177Lu-LCP causes maximum DNA damage after ~48 h, and this damage translates to apoptotic cell 
death shortly thereafter.  177Lu-LCP induces significantly higher maximum H2AX phosphorylation and cell 
death than free 177Lu (p<0.05), and the difference in the pattern of cytotoxic effects between these two 
treatments may be due to a difference in pharmacokinetics/dynamics, as free 177Lu quickly clears from 
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circulation and may deposit into the tumor much earlier, more transiently, and with a different 
intratumoral distribution than 177Lu-LCP. 
3.4.8: Mechanisms of Tumor Growth Inhibition: Microenvironment Studies 
Changes in the tumor microenvironment were observed as well: Figure 3.12 shows that a diffuse 
and disordered fibroblast structure was present two days after treatment with 177Lu-LCP, in contrast to 
the organized fibroblast structure present in untreated and control-treated tumors of the same size (see 
higher magnification images in Figure 3.12 D-E).  These images clearly show that the fibroblasts in 
untreated tumors can organize into a defined morphology to form tumor nests, while those fibroblasts 
in tumors that have been treated with 177Lu-LCP are dispersed and without this mature organization.  
Four days after treatment, the disorganized fibroblast structure persisted (Figure 3.13 A-D), along with 
changes in the collagen structure in the tumor, in which the long swaths of collagen in the untreated 
tumor had been replaced with shorter and more tortuous collagen fibers (Figure 3.13 E-H).  It is known 
that the organized fibroblast structure and more ordered, linearized, and bundled collagen fibers 
present in the untreated tumor are associated with a more mature and malignant phenotype, while a 
disordered fibroblast structure with short, tortuous collagen fibers like those of the treated tumor 
suggest a tumor microenvironment less structurally and functionally capable of growth and progression 
[99-103].   
We also desired to measure the intratumoral localization of Lu-LCP.  Unlike traditional 
chemotherapeutics that must enter the target cell in order to impart their therapeutic effect, internal 
radiotherapy can damage cells at a distance several cell lengths from the source.  β-particles from 177Lu, 
for example, have a maximum energy of ~500 keV, allowing an average path length in tissue of 200-300 
μm [89] and a maximum path length of ~4x that value [37].  177Lu-LCP may then be able to provide 
therapeutic effect to cells that did not take up the particles, which is especially important given the 
intratumoral heterogeneity of nanoparticle delivery in general.  We supposed that a majority of cells in a 
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tumor would be “in range” for β-particle damage after 177Lu-LCP distribution, but desired to measure the 
intratumoral localization of 177Lu-LCP in order to calculate this important spatial relationship between 
cells and particles.  The lipid membrane of the LCPs used in the experiment described in Figures 3.13 and 
3.15 were labeled with fluorescent DiI, and excess DiI was purified away using sucrose gradient 
centrifugation in order to measure the dispersion of the particles throughout the tumor.  Tumor 
sections from several areas in different tumors were then analyzed to quantify distances between cells 
and nanoparticles.  Figure 3.14 shows that nearly 100% of cells in the field are within just 50 μm of the 
nearest Lu-LCP, well within the average path length of a β particle, even though the only nanoparticles 
considered are those present in that 2-D plane—Lu-LCPs residing in the z-direction would only increase 
the particles in range for a given cell.  This substantiates the claim that although not all tumor cells have 
taken up particles, all are susceptible to the delivered therapeutic payload.    
3.4.9: Toxicity Studies 
To gauge the cumulative toxicity of 177Lu-LCP in mice, we treated healthy immunocompromised 
nude mice and healthy immunocompetent CD-1 mice with a single dose of 250 µCi of 177Lu-LCP, the 
highest dose used in this study. Mice were sacrificed 12 days after treatment to assess the cumulative 
effect of the radiation.  At the conclusion of the 12-day study, mouse organs were dissected and 
sectioned, serum markers for kidney and liver toxicity were measured (ALT, AST, BUN, and creatinine), 
and whole blood from the immunocompetent CD-1 mice was analyzed for changes in white blood cell 
count (WBC), hematocrit (HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin count 
(HGB), and platelet count (PLT).  These results were compared against appropriate controls and against 
the normal range for these values.  Morphologies of kidney, liver, heart, lung, skin, and small intestine 
sections after H&E staining showed no difference from normal tissue in nude mice (Figure 3.15) or in CD-
1 mice (Figure 3.16).  Serum markers for renal and hepatotoxicity also remained in the normal range in 
both nude and CD-1 mice (Table 3.4A-B) after treatment.  The data do show some well-tolerated side 
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effects as a result of this treatment, including differences in spleen morphology as well as a decrease in 
white blood cell and platelet counts outside the normal range.  Hematological side effects are common 
during cancer therapy and are easily handled using immune boosters, etc., which were not used in this 
study.  None of these side effects translated to a decrease in mouse body weight (Figure 3.9).   
3.5: Discussion 
In this paper, we have described a novel method for systemic internal radiotherapy by extending 
the anticancer application of our LCP platform to include a theranostic nanoparticle with high specific 
drug loading.   The preferential uptake of 177Lu into LCP allows a huge amount of 177Lu to be 
encapsulated in a very small batch of particles without changing the LCP’s morphology or encapsulation 
efficiency.  The difficulty of nanoparticle scale-up that is pervasive throughout this field is therefore 
eliminated, as a therapeutic dose for a mouse or a human can be made on the same benchtop.   
The theranostic advantage of radioisotope loading into LCP should also not be understated.  
177Lu’s γ emissions permitted live in vivo imaging using SPECT to measure tumor accumulation of 177Lu-
LCP, paving the way for future delivery to orthotopic tumors that will represent a more clinically 
relevant “diagnostic” procedure.  The β decay from 177Lu also causes significant tumor inhibition via DNA 
double-stranded breaks while simultaneously inducing Cerenkov radiation for imaging.  Because 
therapeutic β-emissions are also the imaging contrast agent, Cerenkov imaging is a wonderful example 
of a theranostic application.  Compared to SPECT, Cerenkov imaging correctly estimated the general 
biodistribution of 177Lu-LCP at a fraction of the time and cost.  This opens up opportunity for several 
applications such as dynamically looking at early stages of biodistribution and clearance by taking many 
images in quick succession.  Because the high loading of Lu into LCP is broadly applicable to several 
other polycationic radiometals, such as the β-emitter and effective Cerenkov agent 90Y, it is worthwhile 
to discuss Cerenkov imaging as an interesting and useful theranostic application.  
48 
 
As a follow-up to our tumor inhibition data, we were interested in assessing any significant 
changes in the tumor microenvironment as a result of this treatment, and we evaluated these changes 
by measuring the fibroblast and collagen structure in the tumor.  The changes in the tumor 
microenvironment may be explained by looking deeper into how β-radiation causes the double-
stranded DNA breaks that are shown to be elevated in the treated tumors.  Generally, β-radiation is 
classified as having low linear energy transfer (LET); that is, the β-particles deposit a small fraction of 
their energy per unit length as they travel along their path [37].  In most cases, the DNA damage does 
not occur via direct interaction between a DNA strand and the β-particle itself.  In the case of low LET 
emitters like 177Lu, it is known that most DNA damage is caused by an increase in reactive oxygen species 
(ROS) generated as the emitted β-particles interact with and radicalize water molecules along their path.  
The induced ROS then damage DNA and cause single and double-stranded breaks in an “indirect 
radiation effect” [37].   
Oxidative stress is known to cause many changes in the cellular and extracellular environment, 
especially in rapidly remodeling tissues like cancer, where actin and collagen are just some of the 
proteins susceptible to oxidative damage [104-108].  Actin is an important structural component of cells 
and is also a structural player in the adherens junctions between 3T3 fibroblasts [109].  The cysteine 
residues on actin are susceptible to oxidative damage, and this damage can prevent polymerization, 
cause depolymerization, and affect the organization of actin in cells, potentially restricting the 
organization of fibroblasts in the tumor.  Collagen stability is also affected by oxidative damage, as 
scissions in the collagen α-bands can decrease the degradation temperature of the collagen to below 
body temperature and prevent the formation of collagen fibrils [105, 106].  These results suggest that 
cumulative ROS damage may cause the observed changes in the overall in vivo collagen and fibroblast 
structure shown in Figures 3.13 and 3.14, prohibiting the dynamic formation of bundled collagen and 
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organized fibroblast structures that have been implicated in the formation of resistant tumor nests 
found in more advanced and aggressive tumors.  
Tumor growth inhibition via 177Lu-LCP may then occur by taking advantage of both the 
uncontrolled growth and the excessive microenvironment remodeling observed in cancer.  The low, 
continuous dose of radiation damages tumor cell DNA that can have fewer active repair mechanisms 
and divide much more rapidly than healthy cells while inhibiting the progression of the 
microenvironment toward malignancy.  This allows sustained cancer treatment at a dose that preserves 
the health of the subject. 
Part of the beauty of this approach to radioisotope loading is its broad application for many 
trivalent radiometals, such as other therapeutic radionuclides like 90Y or 192Ir, which are great candidates 
for future work in this subject. Combination therapy using a radiotherapeutic and a radiosensitizing 
chemotherapeutic residing in the same LCP particle should also be possible, given that many small 
molecule drugs have previously been encapsulated in LCP.   
Future work should also investigate whether systemic administration of a radiotherapeutic LCP 
is the most effective dosing method.  Macro and micro-dosimetric calculations should be used to 
determine absorbed doses in the mouse and how the distribution of nanoparticles necessitates different 
calculations than doses from an external beam.  In one potential local delivery scenario, highly loaded 
177Lu-LCP, 192Ir-LCP, or 90Y-LCP could be directly injected into prostate tumors to create a sort of nano-
brachytherapy, in which modified particles would disseminate locally and stably in the prostate but 
remain out of the systemic circulation.   
3.6: Conclusions 
Radionuclide loading into 177Lu-LCP can be increased by several orders of magnitude without 
affecting the 177Lu encapsulation efficiency or LCP morphology, generating a nanoparticle with high 
radioisotope concentration that overcomes scale-up barriers typical of nanotherapeutics and minimizes 
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heavy metal-based toxicities.  The choice of 177Lu as a model radionuclide has allowed in vivo anticancer 
therapy via DNA damage and microenvironment remodeling, in addition to permitting live animal 
SPECT/CT and Cerenkov imaging.  As studies in LCP-mediated radionuclide therapy continue, other 
nuclides may be considered, perhaps in combination with chemotherapeutics, for several different 
therapeutic approaches. 
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Figure 3.1: 177Lu-LCP Formulation.  A) Schematic depicting general formulation procedure.  B) TEM 
image of final 177Lu-LCP.  C) TEM image of final 177Lu-LCP with uranyl acetate negative stain applied.  
Scale bar represents 100 nm. 
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Properties of 177Lu-LCP 
Diameter (nm) 36.2 ± 9 
Zeta Potential (mV) -6.7 ± 3.5 
PDI 0.27 ± 0.05 
 
Table 3.1: 177Lu-LCP Characterization.  Diameter, zeta potential, and PDI measurements taken in 
triplicate after sucrose gradient purification. 
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Figure 3.2: 177Lu-LCP Encapsulation Efficiencies.  Encapsulation efficiencies calculated at increasing 
levels of lutetium.  177Lu EE decrease begins around 1:100 Lu:Ca.  n = 2-3. 
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Lu:Ca Input 
(mols) 
PO4 Input   
(mols) 
Total Lu Input 
(mols) 
Input Activity* 
(mCi) 
177Lu EE Output Activity (mCi) 
1:1x107 2.0x10-6 1.0x10-12 0.0035 0.68 0.0024 
1:100,000 " 1.0x10-10 0.354 0.70 0.25 
1:1000 " 1.0x10-8 35.4 0.69 24.4 
1:100 " 1.0x10-7 354 0.61 217 
1:9 " 1.1x10-6 3933 0.22 865 
1:1 " 1.0x10-5 35400 0.19 6549 
 
Table 3.2: Loading of Isotope into 177Lu-LCP.  177Lu-LCP inputs and output activity based on a specific 
activity of 20 Ci/mg of lutetium, the minimum standard for PerkinElmer delivery.  Ca is always given at 
a 5x molar excess of PO4.  Highest level of stable LCP formulation is 1:1000 Lu:Ca.  A trace amount of 
177Lu was supplemented with nonradioactive 175Lu to achieve the proper Lu:Ca ratio. 
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Figure 3.3: 177Lu-LCP Morphologies at Different Lu:Ca Inputs.  A-F) TEM images of 177Lu-LCP at 
varying Lu inputs. G) Percent Lu in output 177Lu-LCP based on Lu:Ca inputs, calculated by energy 
dispersive X-ray spectroscopy (EDS).  *Lu not detected; negligible small LCP population 
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Figure 3.4: 177Lu-LCP Pharmacokinetics and Biodistribution.  A) The PK curve of i.v. injected 177Lu-LCP fit 
to a two-compartment model; n = 5.  B) Organ BD at t = 24h after i.v. injection of 177Lu-LCP or free 
177LuCl3; n = 3-4. H460 tumor and UMUC3/3T3 (U/T) tumor were subcutaneously inoculated in 
different mice.  *BD of free 177Lu was not tested in H460 tumor-bearing mice.   
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Figure 3.5: 177Lu-LCP and Free 177Lu-Cl3 Pharmacokinetics.  Data represented as mean ± SEM.  n = 5 for 
177Lu-LCP and n = 3 for free 177LuCl3. 
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Figure 3.6: 177Lu-LCP Imaging via SPECT. SPECT/CT images of nude mouse bearing subcutaneous 
UMUC3/3T3 tumor on left flank at 24 h after injection of 177Lu-LCP (Figures 5A-E) or free 177Lu (Figures 
5F-H).  Mouse slit collimator was used for whole body imaging: A) left sagittal, B) coronal, C) 
midsagittal, F) mid-sagittal and G) coronal views.  Pinhole collimator was used in D), E), and H) for 
higher resolution axial and left sagittal views.  177Lu-LCP accumulated in tumor, liver, and spleen, while 
free 177Lu accumulated in the bone and kidneys, but not in the tumor. 
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Figure 3.7: Cerenkov Imaging of 177Lu-LCP. Images of Cerenkov luminescence in nude mice bearing 
subcutaneous UMUC3/3T3 tumor on left flank.  Luminescence image (A) and plain photograph (B) in 
mouse 24 h after injection of 2.5 mCi 177Lu-LCP.   Luminescence image (C) and plain photograph (D) in 
mouse 24 h after injection of 2.5 mCi free 177LuCl3.  Optical images demonstrated 177Lu-LCP 
accumulation in liver, spleen, and tumor, while free 177LuCl3 mainly accumulated in the spine.  Data 
was acquired by an IVIS optical system. 
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Free 177LuCl3 177Lu-LCP 
  %ID %ID/gram %ID %ID/gram 
Blood 0.01 0.02 0.55 0.72 
Liver 3.24 3.59 55.17 69.30 
Spleen 0.13 2.84 3.97 181.25 
Kidney 2.16 7.40 0.25 0.96 
Heart 0.05 0.53 0.34 2.83 
Lung 0.10 0.72 1.15 5.63 
Tumor 0.08 1.25 0.47 9.97 
Spine 2.50 12.58 1.66 6.43 
 
Table 3.3: Biodistribution of 177Lu in mice shown in Figures 3.6-3.8.  Mice were sacrificed after SPECT 
and Cerenkov measurements at t=24 h and organs were harvested.  Left columns show organ 
accumulation in mouse given free 177LuCl3.  Right columns show organ accumulation in mouse given 
177Lu-LCP.  Organ biodistributions measured using gamma scintillation. 
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Figure 3.8: In Vivo Tumor Growth Inhibition in Two Subcutaneous Xenograft Tumor Models. 
Nonradioactive 175Lu was loaded into LCP NPs to act as a vehicle control.  One dose per mouse was 
delivered intravenously on Day 0 (arrows).  A) Human UMUC3 bladder cancer supplemented with 
murine 3T3 fibroblasts.  B) Human H460 non-small cell lung cancer.  Initial tumor sizes ~100-150 mm3; 
n = 5-8; †p<0.03, ‡p<5e-5, *p<0.015. 
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Figure 3.9: Relative Change in Body Weight.  The H460 tumor-bearing mice used in the tumor growth 
inhibition experiment shown in Figure 7B did not significantly lose or gain weight during the 
experiment. 
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Figure 3.10: Tumor Distribution of 177Lu-LCP. A) 24 h after injection with DiI-177Lu-LCP, UMUC3/3T3 
tumors show more homogeneous tumor accumulation of DiI-labelled NP (red).  B) Untreated 
UMUC3/3T3 tumors have more vasculature than H460 tumors, shown as more CD-31 positive area 
(orange). 
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Figure 3.11: Cytotoxicity of 177Lu-LCP in vivo. Mice were treated with 200 µCi of 177Lu-LCP or controls 
and were killed one, two, or four days after administration.   Figure panel A shows p-H2AX-positive 
cells (red) in UMUC3/3T3 tumor sections with or without DAPI (blue).  Figure panel B shows TUNEL-
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positive cells (green) in tumor sections with and without DAPI (blue).  Sections in Figure panel B are 
taken from an adjacent section to those displayed in Figure Panel A.  Five representative fields were 
quantified for TUNEL or p-H2AX-positive cells.  Images appearing in Figure panels A and B represent 
the field with the third-highest quantification.  Average values are shown in Figure C: highest p-H2AX 
upregulation (red) occurred two days after 177Lu-LCP treatment, while highest TUNEL induction (green) 
occurred 4 days after 177Lu-LCP treatment.  *p < 0.007; **p < 0.0005 compared to control.  Scale Bar = 
100 μm. 
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Figure 3.12: Treatment-Induced Changes in Fibroblast Structure.  UMUC3/3T3-GFP (green) tumor 
sections, with tumor nests outlined in white.  Row A) Untreated tumors.  Row B) t = 2 days after 
treatment with cold DiI-175Lu-LCP (red).  Row C) t = 2 days after treatment with hot DiI-177Lu-LCP (red).  
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Row D) High magnification images t = 2 days after treatment with cold DiI-175Lu-LCP (red).  Row E) High 
magnification images t = 2 days after treatment with hot DiI-177Lu-LCP (red); disorganized fibroblast 
structure does not allow tumor nest formation.  Each row shows representative photographs from 
each group, consisting of several tumors and tumor sections. Scale Bar = 300 µm for rows A-C and 50 
µm for rows D-E. 
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Figure 3.13: Treatment-Induced Changes in Microenvironment. Microenvironment structure in 
UMUC3/3T3 tumor sections t = 4 days after treatment with 177Lu-LCP: A-D) Stain for fibroblast marker 
α-SMA (green) in UMUC3/3T3 tumor sections.  Figures A and C show α-SMA expression in an 
untreated tumor and in a tumor at t = 4 days after treatment with 177Lu-LCP; scale bars = 200 μm.  
White dashed boxes are zoomed in in Figures B and D; scale bars = 20 μm.  E-H) Trichrome stain in 
tumors that are untreated (E) or t = 4 days after treatment (F).  Inserts G-H on bottom right have been 
processed to show a more isolated view of the collagen stain.  Arrows show the location of the region 
in the insert.   Scale bar = 50 μm.   
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Figure 3.14: Quantification of DiI-177Lu-LCP Distribution.  Quantification at t = 2 days: A) UMUC3/3T3-
GFP tumor given DiI-177Lu-LCP; scale bar = 500 μm; B) Isolated DiI signal from panel A; C) Heat map 
showing each cell’s distance from its nearest Lu-LCP, where black and blue areas show areas of close 
proximity between cells and particles; D) Quantification of relative cell distance from Lu-LCP; n = 
1.75x106 cells in 8 sections; n = 4 sections each for 177Lu-LCP and 175Lu-LCP. 
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Figure 3.15:  Nude Mouse Toxicity Considerations via Histology.  Healthy nude mouse organs fixed, 
sectioned, and stained with hematoxylin and eosin 12 days after treatment with 250 µCi 177Lu-LCP or 
controls to test cumulative toxicity.  Some acellular regions (arrow) are visible in spleens treated with 
177Lu-LCP.  Scale bar = 150 μm. 
 
 
 
 
71 
 
 
Figure 3.16: CD-1 Mouse Toxicity Considerations via Histology.  Healthy CD-1 mouse organs fixed, 
sectioned, and stained with hematoxylin and eosin 12 days after treatment with 250 µCi 177Lu-LCP or 
controls to test cumulative toxicity.   Scale bar = 150 μm. 
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A) Nude Mice BUN (mg/dL) 
Creatinine 
(mg/dL) 
AST   
(U/L) 
ALT 
(U/L) 
Untreated 23 ± 0.5 0.1 ± 0 99 ± 13 37 ± 2 
175Lu-LCP 23 ± 1.0 0.1 ± 0 102 ± 2 34 ± 5 
250 μCi Free 177Lu 20 ± 1.7 0.1 ± 0 88 ± 16 41 ± 1 
250 μCi 177Lu-LCP 24 ± 1.9 0.1 ± 0 73 ± 4 40 ± 4 
Normal Range 8-33 0.2-0.9 54-298 17-77 
 
B) CD-1 Mice BUN (mg/dL) 
Creatinine 
(mg/dL) 
AST   
(U/L) 
ALT 
(U/L) 
Untreated 20 ± 0.3 0.1 ± 0 69 ± 14 33 ± 1 
175Lu-LCP 21 ± 1.3 0.2 ± 0.03 91 ± 12 35 ± 2 
250 μCi Free 177Lu 15 ± 0.7 0.1 ± 0 109 ± 15 41 ± 3 
250 μCi 177Lu-LCP 15 ± 0.5 0.1 ± 0 125 ± 9 45 ± 5 
Normal Range 8-33 0.2-0.9 54-298 17-77 
 
C) CD-1 Mice WBC (103/μl) 
HCT          
(%) 
MCV          
(fl) 
RBC 
(106/μl) 
HGB      
(g/dl) 
PLT 
(103/μl) 
Untreated 4.5 ± 0.2 52.6 ± 0.2 48.9 ± 0.2 10.7 ± 0.1 16.3 ± 0.1 892 ± 36 
175Lu-LCP 5.2 ± 0.7 50.6 ± 1.1 51.0 ± 1.4 10.0 ± 0.5 15.7 ± 0.3 679 ± 54 
250 μCi Free 177Lu 2.3 ± 0.4 47.6 ± 1.7 53.8 ± 3.8 8.9 ± 0.4 14.6 ± 0.3 926 ± 34 
250 μCi 177Lu-LCP 0.3 ± 0.1 38.8 ± 2.2 50.5 ± 1.6 7.7 ± 0.4 12.0 ± 0.6 217 ± 24 
Normal Range 2.6 - 10.1 32.8 - 48.0 42.3 - 55.9 6.5 - 10.1 10.1 - 16.1 780 - 1540 
 
Table 3.4: Toxicity Considerations via Blood Chemistry. Toxicity of 177Lu in mice, measured 12 days 
after treatment with 250 µCi 177Lu-LCP or controls to test cumulative toxicity: A) Serum protein values 
in healthy, but immunocompromised, nude mice; B) Serum protein values in healthy CD-1 mice; C) 
Whole blood analysis in healthy CD-1 mice, measuring white blood cell count (WBC), hematocrit 
(HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin count (HGB), and platelet 
count (PLT).   177Lu-LCP treatment does not present significant cumulative renal/hepatotoxicity, but 
causes a decrease in WBC and PLT.   
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CHAPTER 4: ENHANCING NANOPARTICLE ACCUMULATION AND RETENTION IN DESMOPLASTIC 
TUMORS VIA VASCULAR DISRUPTION FOR INTERNAL RADIATION THERAPY3 
 
4.1: Summary 
Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive 
stroma, high interstitial pressure, and resistant tumor microenvironment.  We have developed a 
combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing 
massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a 
treatment-induced increase in the accumulation and retention of nanoparticles in the tumor.  The 
vascular disrupting agent CA4P is able to increase the accumulation of radiation-containing 
nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is 
maintained over several days.  We use ultrasound to measure the effect of CA4P in live tumor-bearing 
mice, and we encapsulate the radio-theranostic isotope 177Lutetium as a therapeutic agent as well as a 
means to measure nanoparticle accumulation and retention in the tumor.  This combination therapy 
induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and 
allowing further tumor growth inhibition using a cisplatin-containing nanoparticle. 
4.2: Introduction 
We have previously published on the antitumor efficacy of our 177Lu-loaded Lipid-Calcium-
Phosphate (177Lu-LCP) nanoparticles, which provide internal radiation therapy via the beta decay of 177Lu 
as well as live animal imaging via 177Lu’s gamma decay [25].  One dose of these nanoparticles generated 
                                                          
3 This chapter was originally written as a research article and was accepted by the journal Theranostics on 
9/9/2016.  Doi (if published):10.7150/thno.16681. 
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significant and prolonged tumor growth inhibition in two subcutaneous xenograft tumor models with 
initial tumor volumes of 100-150 mm3.  The success of this approach prompted us to gauge whether the 
antitumor effect could be maintained in larger tumors, which present a number of additional, clinically 
relevant challenges to delivery and treatment success, including an increased growth rate, a more 
mature and resistant stromal structure/microenvironment, and increased interstitial pressure that can 
decrease nanoparticle accumulation.  Successful strategies against these large, aggressive tumors may 
therefore translate more effectively into positive patient outcomes in the clinic.  The UMUC3 human 
bladder cancer model, supplemented with murine NIH-3T3 fibroblasts, is histologically similar to 
desmoplastic bladder cancer seen in the clinic and responds to treatment similarly to patient bladder 
cancer as well.  Although smaller UMUC3/3T3 tumors were shown to be sensitive to 177Lu-LCP, we show 
in Figure 4.4 of this paper that in our large UMUC3/3T3 tumor model (initial tumor volumes ~300-400 
mm^3; Volume = (Length x Width x Depth)/2), 177Lu-LCP monotherapy no longer induces a significant 
antitumor effect.  We therefore designed a combination therapy in which the small molecule drug and 
radiosensitizer [110, 111] Combretastatin A-4 Phosphate (CA4P) is used alongside our radioactive 
nanoparticles to induce a multifaceted synergistic effect. 
The microtubule inhibitor CA4P works by binding to the alpha-beta tubulin heterodimer in the 
cell cytoplasm and preventing microtubule polymerization.  Because cellular spindle fibers are 
composed of microtubules, this action has a cytotoxic effect on cells in vitro, preventing separation of 
chromosomes during mitosis and leading to apoptosis via mitotic catastrophe [112].   
Treatment with the vascular disrupting agent CA4P also generates a distinct mechanism of 
cytotoxicity in vivo.  During tumor growth, angiogenesis of new blood vessel endothelium occurs, and 
these endothelial cells must maintain a flat structure in order to provide a stable and open blood vessel 
lumen.  While the cytoskeletons of mature vasculature, such as those found in healthy tissue, are 
composed of actin, the cytoskeletons of newly formed tumor vasculature are composed of microtubules 
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[113].  It has been hypothesized that when microtubule polymerization is inhibited by CA4P, the flat 
structure of the endothelial cells is compromised, causing them to become more round and occlude the 
lumen of the blood vessel [114].  This decreases blood flow to the center of the tumor, depriving the 
cells of oxygen and nutrients.  In extreme cases, the destruction of blood vessel integrity has been 
shown to cause hemorrhage and subsequent necrosis of the surrounding region.  Because mature, 
healthy vasculature has a cytoskeleton made of actin and healthy cells do not frequently divide, CA4P 
has very low toxicity and is tolerable in mice at doses well above 100 mg/kg. 
A recent publication that has used CA4P in combination with nanoparticles has reported that 
the CA4P-induced vessel occlusion limited nanoparticle accumulation to the outer rim of the tumor 
[115], but we have alternatively found that the intratumoral hemorrhage induced by CA4P allows an 
increased accumulation of nanoparticles throughout the tumor.  This additional dose was retained in the 
tumor over several days, and the sustained higher dose combined with the destructive effects of CA4P 
significantly inhibited tumor growth even in our large, stroma-rich tumor model.  
4.3: Materials and Methods 
4.3.1: Materials 
177LuCl3 and 90YCl3 were purchased from PerkinElmer (Waltham, MA).  1,2-dioleoyl-sn-glycero-3-
phosphate (DOPA), and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were purchased from 
Avanti Polar Lipids (Alabaster, AL).  N-(Carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine, sodium salt (DSPE-PEG2000) was purchased from NOF America 
Corporation (White Plains, NY).  DSPE-PEG2000-Anisamide (DSPE-PEG-AA) was synthesized in our lab as 
described previously [91].  Other chemicals and antibodies were purchased from Sigma-Aldrich (St. 
Louis, MO) or Abcam (Cambridge, MA). 
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4.3.2: Cell Lines 
Four different cell lines were used in the experiments described below: UMUC3 human bladder 
cancer cells, NIH/3T3 (3T3) murine fibroblasts, 4T1 murine breast cancer cells, and B16F10 murine 
melanoma cells.  In some experiments, UMUC3 cells that had been stably transfected with green 
fluorescence protein (GFP) and 3T3 cells that had been stably transfected with red fluorescence protein 
(RFP) were used. 
4.3.3: Experimental Animals 
Female athymic nude mice were used for UMUC3/3T3 tumor experiments presented in this 
manuscript.  Balb/c mice were used as syngeneic hosts for 4T1 tumor inoculation, C57Bl/6 mice were 
used as syngeneic mice for B16F10 tumor inoculation, and CD-1 mice were used for toxicity studies.  The 
nude mice were purchased from the National Cancer Institute (Bethesda, MD) and bred at the Division 
of Laboratory Animal Medicine at the University of North Carolina-Chapel Hill.  The Balb/c, C57Bl/6, and 
CD-1 mice were purchased from Charles River labs.  All work performed on these animals was approved 
by the Institutional Animal Care and Use Committee at the University of North Carolina-Chapel Hill, 
protocol #14-045. 
4.3.4: 177Lu-LCP, 90Y-LCP, and LPC Fabrication and Characterization 
The Lipid-Platinum-Chloride (LPC) nanoparticles were fabricated exactly as described in the 
literature [116].  177Lu/90Y-LCP fabrication was slightly modified from what is described in a previous 
publication [25].  Two reverse microemulsions were prepared in round-bottom flasks.  Both 
microemulsion oil phases contained a mixture of 71% Cyclohexane and 29% Igepal CO-520.  For a batch 
size of 1.67 mL oil phase per flask, 50 μL of 200 mM (NH4)2PO4 was added to one flask and 50 μL of 2.5 M 
CaCl2 with up to five additional μL of 177LuCl3 or 90YCl3 in 0.05 M HCl was added to the other under 
stirring.  After mixing separately for five min, the phosphate-containing emulsion was added directly to 
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the calcium-containing emulsion.  After five more min, 26.6 μL of 25 mg/mL DOPA dissolved in 
chloroform was added to the mixture.  After 20 more min of mixing, 3.34 mL of 100% ethanol was added 
to break the emulsion, and the mixture was stirred for 10 more minutes before centrifugation at 
12,600g for 15 min.  The supernatant was then removed (~15% of input 177Lu was removed here) and 
ethanol was again added to wash the pelleted cores.  After addition of ethanol, the vial(s) were vortexed 
to resuspend the nanoparticle cores and centrifuged at 12,600g for 10 min.  After removing the 
supernatant, the organic-soluble cores were dissolved in chloroform and centrifuged again to remove 
any insoluble salts or particles that had not been well-coated with DOPA (~5% of input removed here). 
Purifying the LCP cores in these two ways ensured that 177Lu or 90Y were only present inside the LCP.  
Outer leaflet lipids (OLLs) dissolved in chloroform were then added to the chloroform-soluble cores 
(40:40:18:2 DOTAP:cholesterol:DSPE-PEG2000:DSPE-PEG2000-AA mol:mol:mol) (0.11:1 total OLL:initial 
oil phase v:v; all lipids at 20mM concentration).  In experiments using DiI-labeled LCP, DiI dissolved in 
chloroform was added to the cores with the OLLs (1:100 DiI:total OLL mol:mol).  Chloroform was 
evaporated until the particles and lipids coated the vial in a lipid film.  Particles were then rehydrated to 
the injection volume with 5% glucose in water at 60 oC.  The solution was vortexed and sonicated 
liberally before injection into mice.  The anisamide ligand was used in all formulations to target the 
sigma receptor overexpressed in UMUC3 cells [92]. 
In experiments using DiI-labeled Lu-LCP, sucrose gradient ultracentrifugation (50,000g for 6 h) 
was used to purify DiI-Lu-LCP from excess DiI that had incorporated into excess free liposomes.   
Encapsulation efficiency of 177Lu into 177Lu-LCP was measured by a Model AA2010 “Nucleus” 
Gamma Scintillation Counter or a Capintec Radioisotope Calibrator CRC-127R and calculated as (signal 
from 177Lu in LCP cores)/(signal from 177Lu in input aqueous phase).  Although 90Y is a pure beta emitter, 
secondary emissions were able to be used to calculate the encapsulation efficiency of large doses of 90Y-
LCP using the CRC-127R.  177Lu-LCP, 90Y-LCP, and LPC hydrodynamic diameters were measured using a 
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Malvern Nano ZS dynamic light scattering instrument.  Particle size was corroborated using transmission 
electron microscopy (TEM).   
4.3.5: Cell Viability Assay 
UMUC3 and 3T3 cells were seeded at a density of 2,500 cells/well in a 96-well culture plate.  
UMUC3 cells were incubated in 200 µL/well DMEM containing 10% fetal bovine serum and 1% 
penicillin/streptomycin, and 3T3 cells were incubated in 200 µL/well DMEM containing 10% bovine calf 
serum and 1% penicillin/streptomycin. 24 h later, escalating doses of CA4P were added to the cell 
culture media, n = 6 for each cell type.  After 48 h, 20 μL of working MTT solution was added to each 
well.  ~2 h later, the media was carefully aspirated and replaced with 200 μL DMSO in order to solubilize 
the MTT product.  The DMSO was mixed thoroughly to ensure complete dissolution of the product, and 
each well was measured for absorbance at 570 nm.  Cell viability was calculated as percent of untreated 
wells. 
4.3.6: CA4P Vessel Occlusion 
Nude mice bearing subcutaneous UMUC3/3T3 tumors were sedated with isofluorane and an 
intravenous catheter was inserted into the tail vein.  Mice were transferred to a heated stage and 
ultrasound gel was used to couple a 15L8 ultrasound transducer to the tissue.  An Acuson Sequoia 512 
ultrasound system (Siemens Corporation, Washington DC, USA) was used to capture contrast images 
and parametric maps of blood perfusion. Preclinical ultrasound microbubble contrast agents composed 
of a phospholipid shell and a perfluorocarbon core (diameter ~ 2 μm) were manufactured in house and 
injected into circulation for the contrast imaging experiments.  Microbubbles were continuously infused 
until a steady state concentration in the blood was reached.  A quantitative measure of perfusion was 
obtained using a technique called “Destruction Reperfusion”, where bubbles are cleared from the 
imaging plane using high-amplitude ultrasound pulses, and the tissue is monitored as microbubbles 
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replenish the tissue [117, 118].  Parametric perfusion maps were generated using proprietary Sequoia 
software; the time necessary for each pixel to regain 20% of its original intensity before destruction was 
measured and displayed in a colormap ranging between fast (green) and slow (red) perfusion as can be 
seen in the figure. The reperfusion was monitored for 20 seconds after destruction, and a 3D perfusion 
map was captured by sweeping the transducer across the tumor and performing destruction reperfusion 
at several locations, using a 1mm step size.  The thickness of each section was 0.4 mm, equal to the 
width of the ultrasound beam. The area that was not reperfused in that time frame, shown in black, was 
quantified and averaged for all sections in four separate tumors.  After this initial baseline value was 
recorded, the mouse was treated i.p. with 100 mg/kg CA4P.  At t = 3 h and 24 h after treatment, the 
same four mice were again imaged in the same manner as before. 
4.3.7: Effects of CA4P on UMUC3/3T3 Tumors 
Mice bearing UMUC3/3T3 tumors ~300-400 mm3 in volume were either treated i.p. with 100 
mg/kg CA4P in 200 μL PBS or left untreated.  24 h after treatment, the mice were sacrificed and their 
tumors were dissected.  Tumors were fixed in 10% formalin for 48 h, embedded in paraffin, and 
sectioned.  Three adjacent sections were stained for apoptosis (TUNEL, Promega), blood vessels (CD-31 
immunofluorescence, Abcam), and Masson’s Trichrome.  The Aperio Scanscope at UNC’s Translational 
Pathology lab was used to acquire images of the entire tumor section.  Sections were overlaid using 
ImageJ.   
4.3.8: Tumor Growth Inhibition Studies 
Four different tumor growth inhibition experiments were performed in this study.  In all cases, 
initial tumor volumes for each group averaged ~300-400 mm3, calculated as Volume = (Length x Width x 
Depth)/2.  Five million UMUC3 cells and 2.5 million 3T3 cells were inoculated in a total volume of 100 μL 
and in a 1:3 matrigel:PBS solution (Corning Matrigel Matrix, High Concentration).  Tumor volumes were 
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measured daily.  In groups receiving CA4P, CA4P was always dissolved in PBS and administered i.p. in 
200 ul.  Groups receiving 177Lu-LCP always received a dose of 250 μCi administered via the tail vein.  
Groups receiving 90Y-LCP always received a dose of 125 μCi administered via the tail vein.  Groups 
receiving a combination therapy always received CA4P 3 h before LCP. 
4.3.9: Tumor Accumulation and Retention of 177Lu 
UMUC3/3T3, 4T1, and B16F10 tumors were inoculated in nude, Balb/c, and C57Bl/6 mice, 
respectively.  When tumors reached ~300-500 mm3, half were treated with CA4P followed by a known 
amount of 177Lu-LCP at t = 3 h, and half were treated with 177Lu-LCP only.  Twenty-four h later, the mice 
were sacrificed and their tumors were dissected.  Tumor accumulation of 177Lu was quantified via 
gamma scintillation.  After quantification, the tumors were incubated in formamide for 48 h at 60 oC to 
show the blood in the tumor centers that had been treated with CA4P.  Separate UMUC3/3T3 tumors 
were treated with purified DiI-Lu-LCP and dissected 24 h after treatment.  These tumors were fixed for 
48 h in 10% formalin at 4 oC, incubated in 30% sucrose in PBS overnight, and then frozen in optimal 
cutting temperature (OCT) reagent.  After cutting into the middle of each tumor, a photograph was 
taken to show the extent of the blood-filled region, and two adjacent sections were cut.  One section 
was imaged to show the distribution of DiI in the tumor, and the second section was stained with 
Masson’s trichrome to show the morphology of the section. 
Measurement of 177Lu-LCP retained in the tumor over several days was also quantified by gamma 
scintillation of dissected tumors once those tumors reached a volume of 1000 mm3. 
4.3.10: Prolonged Tumor Necrosis 
Mice bearing UMUC3/3T3 tumors ~300-400 mm3 in volume were treated with 100 mg/kg CA4P 
only or with 177Lu-LCP or 90Y-LCP 3 h after CA4P treatment.  Four days after treatment, mice were 
sacrificed and tumors were dissected.  Tumors were cut into 3-5 pieces to facilitate fixation and were 
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fixed in 10% formalin for 48 h at 4 oC before being embedded in paraffin.  Tumor sections were cut and 
two sections 8 µm apart were stained in two different ways: the first was stained for apoptosis with the 
TUNEL assay and the second was DAB-stained using immunohistochemistry (IHC) against the Ki-67 
proliferation marker.  The images taken from these two nearby sections were overlaid using ImageJ in 
order to compare distribution of apoptosis and proliferation. 
4.3.11: Treatment-Induced Changes in Microenvironment 
Mice were inoculated with UMUC3 cells stably expressing green fluorescence protein and 3T3 
cells stably expressing red fluorescence protein in the same manner as described above.  Treatment 
began when tumors reached a volume of ~300-400 mm3.  On day seven after treatment, the tumors 
were dissected, cut, and fixed in 10% formalin for 48 h, followed by incubation in 1:1 PBS:OCT overnight 
and freezing in 100% OCT.  Representative tumors were sectioned and two adjacent sections were used 
for quantification.  One section was stained with DAPI only and was used to compare the distribution of 
green UMUC3 cells and orange 3T3 cells.  The other section was DAB-stained using IHC against cleaved 
Caspase 3 to measure apoptosis.  In order to gain appropriate resolution for quantification, multiple 
random fields (~4 mm2) from multiple tumors were used to quantify fibroblast density, total cell density, 
and apoptotic cells. 
4.3.12: Additional Treatment with Cisplatin-Containing LPC 
Mice were inoculated with UMUC3/3T3 tumors as described above.  At the time of study 
initiation, there were two groups comprised of tumors ~300-400 mm3 in volume.  One group remained 
untreated, while the other group received 100 mg/kg CA4P + 125 μCi 90Y-LCP.  When the untreated 
group reached an average volume of ~ 800 mm3, half of the tumors received 1.5 mg/kg cisplatin 
formulated in the LPC nanoparticle, and the other half of the tumors received no additional treatment.  
When the group receiving CA4P + 90Y-LCP reached an average volume of ~ 800 mm3, half of those 
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tumors received 1.5 mg/kg cisplatin formulated in the LPC nanoparticle, and the other half of the tumors 
received no additional treatment.  Tumor volumes were measured daily and mice were sacrificed t = 10 
days after the initial treatment. 
To test nanoparticle accumulation in previously treated and untreated tumors, 300-400 mm3 
tumors were treated with CA4P + 90Y-LCP or left untreated, and six days later all tumors were injected 
with 177Lu-LCP.  24 h later, the mice were sacrificed and the tumor accumulation of 177Lu was measured 
via gamma scintillation counting. 
4.3.13: Toxicity Studies 
CD-1 mice were treated with several combination therapies or appropriate controls and were 
sacrificed 10 days after treatment.  Blood and organs were dissected.  Serum levels of AST, ALT, BUN, 
and creatinine were measured, and organs were stained with H&E to measure any changes in tissue 
morphology.  Whole blood was measured for changes in white blood cell count (WBC), hematocrit 
(HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin count (HGB), and platelet count 
(PLT).    
4.4: Results 
4.4.1: CA4P Monotherapy 
We first desired to gauge the relative toxicity of CA4P on UMUC3 and 3T3 cells in vitro, and an 
MTT cell proliferation assay was conducted after the cells were incubated with escalating doses of CA4P 
for 48 h.  Both cell lines responded at low doses, indicating the potency of microtubule polymerization 
inhibition on both cell types. 
The effects of 100 mg/kg CA4P on the blood vessels of large (300-400 mm3), stroma-rich 
UMUC3/3T3 subcutaneous xenograft tumors in vivo were also determined.  We used ultrasound 
microbubble contrast agents to measure the perfusion of blood through tumors before and after i.p. 
83 
 
administration of CA4P.  Microbubbles with diameter ~2 μm were continuously intravenously 
administered via syringe pump during imaging, and an ultrasound transducer recorded the distribution 
of the bubbles in several 0.4 mm-thick sections across the entire length of the tumor (depicted in Figure 
4.2C).  High-amplitude ultrasound was used to pop the bubbles in each section, and time-dependent 
reperfusion of microbubbles back into the section was quantified over a span of 20 s (Figure 4.2A).  
Significant blood vessel occlusion occurred 3 h after treatment, and after 24 h, some but not all of the 
vessel perfusion had normalized.  As reported in literature, the outer rim of each treated tumor at t = 3 
h did not show significantly decreased perfusion.  It is hypothesized that this occurs because these cells 
can be fed by more mature vasculature in the surrounding healthy tissue.    
The decrease in blood perfusion caused by CA4P generated areas of significant apoptosis 24 h 
after treatment, as shown in the green fluorescence image in Figure 4.3B.  Adjacent tumor sections 
show a loss of blood vessel structure in the highly apoptotic area (red), suggesting that some vessels 
undergo permanent damage after CA4P treatment.  High-magnification composite images in Fig 4.3D 
show a lower cell density and reduced vessel structure in apoptotic regions. 
4.4.2: CA4P + 177Lu-LCP Combination Therapy 
Despite the in vitro and in vivo cytotoxic effects of CA4P, treatment with the drug alone is 
completely ineffective against our large, aggressive UMUC3/3T3 tumor model.  Monotherapy with 177Lu-
LCP also does not generate any significant tumor growth inhibition, although when 177Lu-LCP is given i.v. 
three hours after CA4P is given i.p.—the time at which vessel occlusion is highest—tumor growth is 
significantly inhibited compared to 177Lu-LCP alone (Figure 4.4).   
4.4.3: CA4P increases the enhanced permeability and retention (EPR) of tumors 
After observing such a marked decrease in tumor growth rate, we attempted to determine how 
CA4P and 177Lu-LCP were able to work synergistically.  One reason why 177Lu-LCP alone is ineffective may 
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be because in large tumors, the high interstitial pressure limits accumulation of nanoparticles into 
tumors [119].  We found that while the accumulation of 177Lu-LCP was quite low in larger UMUC3/3T3 
tumors receiving 177Lu-LCP alone, if 177Lu-LCP was given 3 h after 100 mg/kg CA4P, its accumulation 
significantly increased (Fig 4.5A).  In two additional large tumor models—a 4T1 orthotopic breast cancer 
model syngeneically grown in Balb/c mice and a B16F10 subcutaneous melanoma model syngeneically 
grown in C57Bl/6 mice—CA4P induced higher tumor accumulation, although for tumor models with 
higher 177Lu-LCP accumulation during monotherapy, the increase in tumor accumulation after CA4P was 
less pronounced.  This could be related to the natural differences in vessel permeability among the 
models.  While the hard, dense UMUC3/3T3 and 4T1 tumors can be described as “stroma-vessel”[120] 
types in which blood vessels grow within a stroma/fibroblast structure, the soft B16F10 tumors grow 
much less densely as “tumor-vessel” type tumors with leakier vasculature, which may contribute to their 
innately high tumor accumulation and insensitivity to changes in nanoparticle accumulation after 
treatment with CA4P. 
Upon cutting a CA4P-treated UMUC3/3T3 tumor in half at t = 24 h (Fig 4.5B, right image), a large 
portion of the tumor interior had become filled with blood, further suggesting that CA4P had indeed 
compromised the integrity of the blood vessels and caused a pool of blood to form in the tumor.  This 
slowly-perfused pool of blood would certainly present as was observed in our ultrasound experiments, 
as the rapid and orderly vascular flow to and from the tumor had been destroyed.   
After the 177Lu-LCP accumulation was quantified in the tumors used in Fig 4.5A, the tumors were 
soaked in formamide for 48 h at 60 oC in order to show the extent of additional blood stuck in the 
tumors.  Representative tumors in Fig 4.5C show that blood pools in both UMUC3/3T3 and 4T1 tumors 
after treatment with CA4P, but does not in untreated tumors of a similar size.  The black melanocytes in 
the B16F10 tumors do not allow us to observe the effect of CA4P, but it is known that untreated B16F10 
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tumors are naturally soft and bloody, a fact that was verified in this study as well.  Again, this could be 
why B16F10 tumors allow greater 177Lu-LCP accumulation and are less affected by CA4P. 
The distribution of 177Lu-LCP in the bloody and non-bloody regions of CA4P-treated tumors was 
also compared.  We desired to know whether CA4P would affect the vessels’ permeability to 
nanoparticles, and whether a significant amount of additional 177Lu-LCP would distribute into the blood 
pool.  The lipid bilayer of 177Lu-LCP was therefore labeled with the fluorescent small molecule DiI—
known to faithfully remain in the labeled lipid bilayers [28, 97]—and the nanoparticles were purified 
using sucrose gradient centrifugation.  t = 3 h after treatment with CA4P, DiI-177Lu-CA4P was given to 
mice bearing UMUC3/3T3 tumors, and 24 h later the mice were sacrificed and their tumors were 
dissected, processed, and frozen in OCT.  After cutting into the middle of each tumor, a photograph was 
taken to show the extent of the blood-filled region (Fig 4.5D, left image), and two adjacent sections 
were cut.  One section was imaged to show the distribution of DiI in the tumor (middle image), and the 
second section was stained with Masson’s trichrome to show the morphology of the section (right 
image).  The average distribution of nanoparticles in all imaged sections (Fig 4.5E, n = 4) showed that 
there was slightly more DiI signal per area in bloody regions, but in a paired t-test comparing DiI 
distribution in each tumor, this difference was not significant (p = 0.19).  This means that the additional 
177Lu-LCP that accumulated after CA4P treatment distributed relatively evenly throughout the tumor and 
not only in the regions where the vasculature became permeable to blood cells.  In those regions where 
blood vessels were not permanently compromised, the loss of the vessel endothelial cells’ flat 
structure—induced by CA4P’s inhibition of microtubule polymerization—may have created gaps 
between the cells and allowed the vessels to become more permeable to nanoparticles, leading to 
higher nanoparticle accumulation in non-bloody regions as well.   
Even though some nanoparticles are delivered to the apoptotic center of the tumor, internal 
radiation therapy is able to deliver treatment to faraway cells, increasing the utility of those particles 
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delivered to the middle of the tumor.  Additionally, because 177Lu slowly decays independent of its 
environment (t1/2 = 6.6 days), if the radiation remains in the tumor, it may prevent regrowth of tumor 
tissue. 
At this point, we had determined that CA4P induces enhanced accumulation of 177Lu-LCP, but 
had not determined whether this additional accumulation could be retained over a significant length of 
time.  It could be that as the pooled blood is filtered out of the tumor over time, it would take many of 
the particles and radioactive cargo with it.  Because radioisotopes decay over time, to be most effective, 
they should remain in the tumor as long as possible, continuously giving a low dose of radiation to the 
tumor.  To test this, mice bearing UMUC3/3T3 tumors ~300-400 mm3 were treated with 100 mg/kg 
CA4P + 250 μCi 177Lu-LCP or controls.  Tumor volumes were measured daily, and the number of days it 
took for each tumor to reach 1,000 mm3 was determined.  When a tumor reached 1,000 mm3, the 
mouse was sacrificed and its tumor was dissected, weighed, and assessed for radiation signal.  We again 
found that CA4P + 177Lu-LCP significantly increased time to reach 1,000 mm3 compared to controls (Fig 
4.6A and B), but more importantly, at the time each tumor reached 1,000 mm3, those tumors that had 
received CA4P + 177Lu-LCP still contained significantly more 177Lu per gram of tumor than those that had 
received 177Lu-LCP alone, even though it took on average ~30% longer for those tumors receiving CA4P + 
177Lu-LCP to reach 1,000 mm3.  This means that those tumors were in fact able to retain the increased 
accumulation of 177Lu over an extended period of time.  The increased vessel permeability leading to the 
increased accumulation of 177Lu-LCP combined with the sustained retention of 177Lu in tumors means 
that CA4P does indeed increase the EPR of 177Lu-LCP. 
4.4.4: Choosing the most effective radionuclide 
177Lu is a relatively new radioisotope that is advancing toward the clinic in a variety of 
applications.  177Lu is a good model isotope because its 6.6 day half-life provides the researcher a 
relatively long time to perform experiments before it decays, and the gamma component of its decay 
87 
 
allows simple quantification of signal as well as live animal imaging using SPECT [25].  Despite these 
advantages, 177Lu has a fairly low beta energy (max = 0.5 MeV) with an average path length in tissue of 
only 200-300 μm [89].  In a large tumor model, it may be better to use an isotope with a more cytotoxic, 
higher energy beta emission that can reach farther away from the source, especially considering the 
heterogeneous delivery of nanoparticles in general and the fact that treatment with CA4P may induce 
regions of higher and lower nanoparticle density.  177Lu was therefore compared to 90Yttrium (90Y), a 
clinically used radioisotope [121, 122] which has a max beta energy of 2.28 MeV and a half-life of 2.67 
days.  Figure 4.7A compares the relative decay of 177Lu and 90Y over a period of seven days, while Figure 
4.7B compares the previously calculated dose kernels for point sources of the two isotopes in units of 
absorbed dose (nanogray per decay per h over a given surface area) [123, 124].  While 90Y decays more 
quickly than 177Lu, its higher beta energy allows more energy to reach farther away from the source and 
impart more energy per interaction. 
Y is a trivalent transition metal that sits just above Lu in group 3 of the periodic table, and is 
therefore very chemically similar to Lu.  Not surprisingly, 90Y can also be easily encapsulated into LCP at 
the same encapsulation efficiency as 177Lu high efficiency (~80%), and changing the LCP cargo from 177Lu 
to 90Y does not change the morphology of the nanoparticles (Fig 4.8A and B).  Because the max beta 
energy of 90Y is ~4x higher than 177Lu and its half-life is ~2x lower, the dose per mouse of 90Y-LCP was set 
at 125 μCi, 2x less than the dose of 177Lu-LCP, in order to more fairly compare the two isotopes.  This is 
common in publications comparing 90Y and 177Lu, often because the maximal tolerable dose for the 
delivered 177Lu is approximately twice as high as that of 90Y [125, 126].  
 
In order to compare the efficacy of 177Lu and 90Y while also determining how their delivery 3 h 
after CA4P might affect the regrowth of apoptotic areas initially generated by CA4P, we measured the 
amount of apoptosis in large tumors four days after treatment with CA4P alone, or after combination 
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therapy with CA4P + 177Lu-LCP or CA4P + 90Y-LCP (Figure 4.9).  After four days, the apoptosis caused by 
CA4P alone had been nearly completely healed and replaced with a high concentration of cells staining 
positively for the proliferation marker Ki-67, while significant apoptosis in the tumor centers still 
remained after combination treatment with CA4P + 90Y-LCP.  After treatment with CA4P + 177Lu-LCP, 
there was a large variation in the apoptotic and proliferative areas of various tumors.  There was an 
increase in apoptotic area when compared to CA4P treatment alone, but this increase was not 
statistically significant.  These results suggested that 90Y-LCP would be more effective at inhibiting tumor 
growth than 177Lu-LCP, and may do so at least in part by maintaining the apoptotic region generated by 
CA4P.   
4.4.5: Tumor Growth Inhibition with 90Y-LCP and LPC 
In the following tumor growth inhibition study, UMUC3 cells stably expressing green 
fluorescence protein and 3T3 cells stably expressing red fluorescence protein (UMUC3-GFP/3T3-RFP) 
were inoculated into mice.  Treatment with CA4P + 90Y-LCP was compared against CA4P + 177Lu-LCP, 
using 90Y-LCP monotherapy as a control alongside the untreated group.  CA4P + 90Y-LCP tumors grew 
significantly more slowly than any other group, including CA4P + 177Lu-LCP (Fig 4.10A).  At the study 
endpoint, the tumors were dissected and processed for frozen sectioning.  Two adjacent sections were 
stained: the first section was stained with DAPI, and fluorescence imaging was used to determine the 
distribution of UMUC3-GFP and 3T3-RFP cells in the tumor (Fig 4.10B and 4.10C); the second section was 
stained using IHC against cleaved Caspase 3 to quantify apoptosis (Fig 4.10D).  The average relative 
fibroblast density, total cell density, and apoptotic cell density across groups was calculated and showed 
that even seven days after treatment with 90Y-LCP + CA4P, the tumors still contained significant amounts 
of apoptosis and the total cell density in the tumor had been decreased by 25%.  In addition, the 
fibroblast density had been greatly reduced, eliminating the aggressive and resistant “tumor nest” 
structure observed in many desmoplastic tumors (Fig 4.10E).   
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Despite these changes to the tumor microenvironment, the tumors continued to slowly grow, 
although it is clear that their microenvironment had become much more susceptible to additional 
treatment.  The lower cell density had undoubtedly decreased the tumor’s interstitial pressure, and the 
loss of fibroblast structure had removed the physical barrier to the remaining tumor cells.  With the 
tumors in this weakened state, it was hypothesized that treatment using a potent nanoformulated drug 
may further decrease the growth rate of these now very large tumors.  Nanoparticles composed nearly 
entirely of cisplatin (termed Lipid-Platinum-Chloride particles, or LPC [28, 116]; characterized in Fig 4.8) 
have been shown to be highly effective against a variety of tumors, but have been ineffective in treating 
large, desmoplastic tumors such as this stroma-rich bladder cancer model.  Although cisplatin is 
generally a potent and effective drug, the fibroblasts in large UMUC3/3T3 tumors physically prevent the 
nanoparticles from reaching the tumor nest in addition to secreting the resistance-forming chemokine 
Wnt16b in response to treatment [127].   In our finaltumor inhibition experiment, we examined whether 
two low doses of LPC given once tumors had grown very large (~800 mm3) could significantly slow the 
growth of untreated tumors or tumors that had previously been given 100 mg/kg CA4P + 125 μCi 90Y-LCP 
(Fig 4.11). 
To fairly compare the efficacy of LPC on previously treated and untreated tumors, LPC was 
initially given when the average volume of tumors within each group reached ~800 mm3.  At those 
points, half of the untreated tumors and half of the previously treated tumors received a total of two 
doses of 1.5 mg/kg LPC, administered i.v. through tail vein injection on two consecutive days (Fig 4.11A).  
Groups were divided evenly to maintain the average tumor volume of each group.   
All tumors were then normalized to the date at which they received LPC and their volume on 
that date (Fig 4.11B).   The rate of tumor growth from the date of initial LPC treatment (or paired 
untreated controls) was then quantified.  In tumors that initially received CA4P + 90Y-LCP, a significant 
difference in growth rate was observed between those tumors that received additional LPC treatment 
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and tumors that received no additional treatment.  In contrast, in tumors that initially received no 
treatment, additional treatment with LPC induced no distinguishable change in growth rate compared to 
completely untreated tumors.  This suggests that the treatment-induced changes in the tumor 
microenvironment shown in Fig 4.10 allowed LPC to provide further tumor growth inhibition even in 
very large tumors.  By increasing the dose or the duration of treatment, further tumor growth inhibition 
can be expected. 
To test our hypothesis that these weakened tumors were still more susceptible to increased 
nanoparticle accumulation—whether because of lower total cell density or otherwise—we treated 300-
400 mm3 tumors with CA4P + 90Y-LCP, six days later injected 177Lu-LCP, and 24 h after that, sacrificed the 
mice and measured the tumor accumulation of 177Lu via gamma scintillation counting.  We compared 
the accumulation of 177Lu in these tumors to the accumulation of 177Lu in previously untreated very large 
(~800 mm3) tumors that had been dissected 24 h after the mice received 177Lu-LCP.  After normalizing 
for tumor mass, we found that those tumors that had been previously treated with CA4P + 90Y-LCP had 
accumulated, on average, 40% more 177Lu than those tumors with no prior treatment, although this 
difference was not statistically significant (p ~ 0.1). 
4.4.6: Toxicity Considerations 
Lastly, we determined if there was any toxicity induced by these radiation and combination 
treatments.  Because internal radiotherapy imparts a slow, continuous dose to tissues, the cumulative 
toxicity generated ten days after treatment was measured.  There was no observed renal or hepatic 
toxicity observed (Table 4.1A), but as expected, the radiation treatments induced a tolerable decrease in 
white blood cell count and platelet count (Table 4.1B).  Interestingly, the treatments incorporating 90Y 
induced less toxicity than the treatments using 177Lu, even though the 90Y was more effective at 
inhibiting tumor growth.  No toxicity was observed in H&E-stained organ sections (Figure 4.12).  
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4.5: Discussion 
While a recent study has shown that vessel occlusion caused by CA4P prevents nanoparticles 
from entering the tumor center [115], we have shown that CA4P induces an enhanced EPR effect, 
allowing an increased accumulation and retention of nanoparticles throughout the tumor.  We have 
observed that the increase in nanoparticle accumulation comes alongside vascular hemorrhage in the 
tumor, and it makes sense that if blood cells can enter the tumor center, the much smaller nanoparticles 
also slowly flowing through the broken vasculature would not be kept at the tumor periphery.  We have 
also observed that the pooled blood in tumors dissected 24 h after CA4P treatment had not yet 
coagulated, suggesting the presence of at least a slow flow of blood capable of bringing nanoparticles 
into the tumor.  What, then, could cause the discrepancy in the data?  The seemingly contradictory 
study also reports vascular hemorrhage, but they administer their nanoparticles at the same time that 
they administer the CA4P.  It could be that the immediate vascular occlusion effect of CA4P, which 
occurs before any hemorrhage begins, stops all flow into the center of the tumor, trapping the 
nanoparticles on the outer rim.  If their particles quickly clear from circulation, by the time vascular 
hemorrhage begins, there are no particles left to enter the inner regions of the tumor.  In contrast, our 
nanoparticles are given 3 h after CA4P treatment, at which point vascular hemorrhage may have already 
begun, allowing an increased amount of particles into the tumor. 
If this is the case, it is worth discussing whether one approach is more effective than another.  
This answer must be given in light of the tumor model being studied.  In the recent article, CA4P alone is 
able to cause vascular hemorrhage across nearly the entire tumor in just four hours, and only a small 
portion of the tumor requires nanoparticle treatment.  Only having a small portion of the tumor 
available for nanoparticle deposition may greatly reduce the overall tumor accumulation of the particle, 
but in this case, the authors show that this is all that is needed.  In our case, although ultrasound images 
suggest that a large percentage of the tumor is not well perfused 3 h after CA4P treatment, some of this 
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vessel occlusion is transient.  The ability of vasculature in UMUC3/3T3 tumors to partially repair after 
treatment with CA4P may be due in part to their stroma-vessel structure, as the organized fibroblasts 
which line the vessel endothelium may provide enough structural support to allow vessel repair.  In 
addition, the TUNEL-positive area 24 h after treatment is variable in size, and is also able to be replaced 
with proliferating cells over time.  In this case, we have shown that the heightened nanoparticle 
accumulation and retention in the tumor is vital for effective tumor inhibition.    Strategies to deal with 
these resistant and aggressive tumors may be different from those aiming to treat tumors with less 
stroma.   
It is important to note that the large tumor model used in this study was chosen not because of 
its size, but because its size provided it with characteristics that are difficult to treat.  The difficulty of 
slowing down the growth of an aggressive, desmoplastic tumor with a mature microenvironment 
requires a synergistic approach that provides the right treatments at the right times.  CA4P 
simultaneously generates apoptosis in a significant portion of the tumor and induces an increased EPR in 
the tumor.  The necrosis in the middle of the tumor is maintained by 90Y-LCP, which also presents 
cytotoxicity to the surviving cells in the tumor.  Changes in the tumor microenvironment in response to 
this combination therapy then allow treatment with LPC nanoparticles, which are completely ineffective 
in tumors that have not been previously treated.  Although these treatments do not cause tumor 
remission, they generate significant tumor growth inhibition in this tumor model that will grow tenfold 
in ten days if left untreated. 
4.6: Conclusion 
In conclusion, we have generated significant tumor growth inhibition in a large, desmoplastic 
tumor model by using CA4P to increase the tumor EPR and allow increased accumulation and retention 
of radioactive nanoparticles for internal radiation therapy.  This combination therapy decreases the 
fibroblast and overall cellular density in the tumor, allowing effective treatment with a second 
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nanoparticle system containing cisplatin—an approach which may also be effective as a local 
combination therapy against desmoplastic cancers in the liver using methods of selective internal 
radiation therapy.   
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Figure 4.1: In Vitro Effects of CA4P. UMUC3 and 3T3 proliferation under CA4P dosing in vitro; drug 
incubated with cells for 48 h; n = 6  
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Figure 4.2: CA4P-Induced Vessel Occlusion.   Nude mice bearing subcutaneous UMUC3/3T3 tumors 
were imaged using a microbubble ultrasound contrast agent at a baseline level and at t = 3 h and 24 h 
after i.p. administration of 100 mg/kg CA4P.  Untreated group not given CA4P.  Microbubbles estimate 
speed of blood perfusion in the tumor.  A) Middle section of a representative tumor from each group 
and time point.  B) Quantification of tumor volume that was not perfused to 20% of initial 
microbubble concentration 20 sec after destruction, n = 4.  **p < 0.01; Baseline CA4P compared to 
CA4P at t = 3 h.  C) Image acquisition scheme. 
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Figure 4.3: Effects of CA4P on UMUC3/3T3 Tumors.  A) Adjacent untreated tumor sections stained 
with DAPI (cell nucleus, blue), TUNEL (apoptosis, green), CD-31 immunostain (blood vessels, red), or 
Masson’s Trichrome.  Composite image formed from overlay of DAPI, TUNEL, and CD-31 stains.  Scale 
bar (A, B, C) = 1 mm.  B) Adjacent sections of tumor 24 h after mouse was treated with 100 mg/kg 
CA4P i.p.  Stainings match those in (A).  C) Composite image of four representative treated tumor 
samples 24 h after 100 mg/kg CA4P.  D) Zoomed composite image; scale bar = 200 µm.  E) Zoomed 
composite image; scale bar = 100 µm. 
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Figure 4.4: In Vivo Effects of CA4P + 177Lu-LCP.  Tumor growth inhibition in UMUC3/3T3 stroma-rich 
bladder cancer subcutaneous xenograft tumor model.  On Day 0, 100 mg/kg CA4P was administered 
i.p. 3 h before i.v. treatment with 250 μCi 177Lu, either as 177LuCl3 or formulated as 177Lu-LCP.  No 
subsequent doses were given.  Initial tumor sizes = 300-400 mm3; n = 5-7; **p<0.01 compared to 177Lu-
LCP. 
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Figure 4.5: Tumor Accumulation of 177Lu.  A) Subcutaneous tumor accumulation of 177Lu 24 h after i.v. 
administration of 177Lu-LCP with or without 100 mg/kg CA4P given i.p. 3 h earlier.  UMUC3/3T3 tumors 
inoculated in nude mice; n = 8.  4T1 tumors inoculated in Balb/c mice; n = 4.  B16F10 tumors 
inoculated in C57BL/6 mice; n = 4-5.  B) Image of UMUC3/3T3 tumors untreated (left) or 24 h after 
treatment with 100mg/kg CA4P i.p. (right); Scale bars ~ 5mm.  C) Three tumor types incubated in 
formamide for 48 h at 60 oC show blood in their centers when treated with CA4P; scale bar ~5mm.  D) 
UMUC3/3T3 tumor 24 h after treatment with 100 mg/kg CA4P; left panel: photograph of tumor tissue 
frozen in OCT during sectioning, bloody area outlined in black; middle panel: distribution of DiI-177Lu-
LCP in tumor; right panel: H&E stained section adjacent to section taken for middle panel.  Scale bar = 
1 mm.  E) Quantification of DiI-177Lu-LCP in bloody and non-bloody regions of tumor sections; n = 4. 
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Figure 4.6: Tumor Retention of 177Lu-LCP .  A) Kaplan-Meier plot of mouse tumor growth to 1,000 mm3, 
n = 6-7.  B) Median time to reach 1,000 mm3 in mice receiving 250 μCi 177Lu-LCP with or without 100 
mg/kg CA4P i.p.  C) Tumor accumulation of 177Lu when tumors reach 1,000 mm3.   
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Figure 4.7: Comparison of 177Lu and 90Y.  A) Different half-lives result in quicker drop-off of activity 
over time for 90Y.  B) Graphical display of dose kernels representing absorbed dose at increasing 
distances from a point source in an infinite water medium; decay products from 90Y are better able to 
impart energy to targets at longer distances from the source. 
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Figure 4.8: Nanoparticle Characterization using TEM and DLS.  A) TEM image of 177Lu-LCP cores; B) TEM 
image of 90Y-LCP cores. C) TEM image of LPC cores. D) DLS number distribution of final nanoparticle 
size; Red = 177Lu-LCP, Green = 90Y-LCP. E) DLS number distribution of final LPC nanoparticle size   
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Figure 4.9: Combination Treatment Prolongs Tumor Necrosis.  (A), top row: four days after CA4P 
monotherapy or combination treatment with 250 μCi 177Lu-LCP or 125 μCi 90Y-LCP, tumors from 
several mice were dissected, sectioned, and stained for apoptotic cells (TUNEL, green).  Middle row: 
sections 8 μm away from TUNEL sections were stained with proliferation marker Ki-67 using IHC 
(brown).  Bottom Row: Ki-67 (yellow) overlaid with TUNEL (green).   Scale bar = 2 mm.  B) 
Quantification of TUNEL-positive area, n = 8 (CA4P), 30 (CA4P + 177Lu-LCP), 15 (CA4P + 90Y-LCP). 
 
 
 
 
 
 
103 
 
 
Figure 4.10: In Vivo Comparison of 177Lu-LCP and 90Y-LCP. Mice bearing UMUC3-GFP/3T3-RFP tumors 
of volume 300 – 400 mm3 were treated as shown in A), n = 5-6 mice.  On Day 7, tumors were 
harvested, processed, sectioned in OCT, and stained.  B) representative tumors shown from each 
group; green = UMUC3-GFP, orange = 3T3-RFP.  Scale bar = 2 mm.  C) 3T3-RFP signal isolated to show 
distribution. D) Caspase 3 distribution in adjacent section to (B).  E) Quantification of fibroblast 
density, total cell density, and apoptosis from each group.  Image resolution for quantification was 
enhanced by quantifying several random areas at higher magnification, ~4 mm2/section.  n = 9-13.  
***p < 0.001; *p < 0.05. 
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Figure 4.11: Tumor Growth Inhibition with Addition of LPC: Mice bearing UMUC3/3T3 tumors of 
volume 300 – 400 mm3 were either treated with 100 mg/kg CA4P + 125 μCi 90Y-LCP or left untreated (n 
= 10).  When tumors reached ~800 mm3, half of the mice from each group (n = 5) were treated with 
100 mg/kg CA4P; t = 0
125 μCi 90Y-LCP; t = 3 h
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1.5 mg/kg CDDP formulated in LPC nanoparticles on two consecutive days.  A) Tumor volumes 
recorded daily.  B)  All four groups normalized to the volume of each individual tumor at the time of 
initial CDDP dose.  *p < 0.05; ***p < 0.001. 
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Table 4.1: Toxicity studies.  Values measured 10 days after treatment in immunocompetent CD-1 mice 
to test cumulative radiation toxicity: A) Serum protein values for all treatment groups, measuring 
blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), and aspartate 
aminotransferase (AST). B) Whole blood analysis for all treatment groups, measuring white blood cell 
count (WBC), hematocrit (HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin 
count (HGB), and platelet count (PLT).  
 
WBC 
(103/μl)
HCT          
(%)
MCV          
(fl)
RBC 
(106/μl)
HGB      
(g/dl)
PLT 
(103/μl)
Untreated 3.8 ± 0.4 57.5 ± 0.9 60.6 ± 1.1  9.5 ± 0.3 15.6 ± 0.3 936 ± 30
CA4P 3.4 ± 0.4 50.3 ± 3.6 52.8 ± 3.6 9.3 ± 0.3 15.5 ± 0.4 980 ± 39
250 uCi 177Lu-LCP 0.4 ± 0.1 42.9 ± 1.8 53.4 ± 1.8 8.0 ± 0.1 12.7 ± 0.2 221 ± 35
125 uCi 90Y-LCP 0.8 ± 0.1 36.8 ± 1.1 49.7 ± 0.7 7.4 ± 0.3 11.9 ± 0.5 556 ± 131
CA4P + 250 uCi 177Lu-LCP 0.4 ± 0.1 43.5 ± 4.5 56.3 ± 1.7 7.7 ± 0.6 12.4 ± 0.9 150 ± 25
CA4P + 125 uCi 90Y-LCP 0.8 ± 0.1 38.6 ± 3.1 53.7 ± 2.9 7.2 ± 0.2 11.8 ± 0.5 463 ± 45
CA4P + 125 uCi 90Y-LCP + LPC 1.1 ± 0.1 41.0 ± 3.5 53.2 ± 2.7 7.7 ± 0.4 13.1 ± 0.7 384 ± 38
Normal Range 2.6 - 10.1 32.8 - 48.0 42.3 - 55.9 6.5 - 10.1 10.1 - 16.1 780 - 1540
BUN mg/dL Creatinine mg/dL AST U/L ALT U/L
Untreated 19.0 ± 1.4 0.18 ± 0.03 34.25 ± 1.7  39.0 ± 1.7
CA4P 17.5 ± 0.6 0.2 37.0 ± 3.2 44.3 ± 4.6
250 uCi 177Lu-LCP 18.5 ± 1.3 0.2 29.3 ± 2.2 45.5 ± 2.3
125 uCi 90Y-LCP 22.0 ± 1.7 0.2 29.5 ± 2.2 44.3 ± 3.3
CA4P + 250 uCi 177Lu-LCP 23.5 ± 1.9 0.2 34.3 ± 2.5 40.3 ± 2.4
CA4P + 125 uCi 90Y-LCP 21.8 ± 1.3 0.2 33.5 ± 1.8 44.3 ± 2.2
CA4P + 125 uCi 90Y-LCP + LPC 19.6 ± 0.9 0.2 ± 0.02 60.2 ± 23.7 37.2 ± 6.6
Normal Range 8-33 0.2-0.9 54-298 17-77
A
B
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Figure 4.12: Histology.  Healthy CD-1 mouse organs fixed, sectioned, and stained with hematoxylin 
and eosin 10 days after treatment to test cumulative toxicity.   Scale bar = 150 μm. 
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CHAPTER 5: SUMMARY AND FUTURE STUDIES 
 
5.1: Summary of Current Work 
In this work, we have synthesized a radio-theranostic nanoparticle capable of encapsulating a 
number of radiometals by virtue of their low solubility with phosphate.  Because cationic atoms such as 
Lu, Y, and Cu are able to outcompete calcium for precipitation with phosphate in the nanoparticle cores, 
both very high and very low loading of isotope into LCP can be achieved without changing any other 
inputs.  This not only allows flexibility and reproducibility among many different batch sizes and 
applications, but overcomes the scale-up barrier pervasive in the field of nanoparticle therapy, 
permitting human-scale synthesis on the benchtop.  This high specific loading can be achieved in 
nanoparticles that are still overwhelmingly composed of calcium phosphate. 
We have found that 177Lu-LCP is an effective SPECT and Cerenkov imaging agent, and 
monotherapy with 177Lu-LCP provides effective cancer therapy in two smaller tumor models.  Tumor 
growth inhibition occurs by means of DNA double-stranded breaks that subsequently trigger apoptosis 
in tumor cells.  Additionally, treatment with 177Lu-LCP can modify the tumor microenvironment by 
preventing the organization of fibroblasts into a more mature structure.  Unfortunately, if treatment 
begins after this aggressive and resistant microenvironment forms, 177Lu-LCP alone is insufficient to 
decrease the tumor growth rate.   
In order to treat these aggressive, desmoplastic tumors, a combination treatment strategy was 
devised, coupling 177Lu-LCP with the vascular disrupting agent CA4P.  Monotherapy with CA4P causes 
massive hemorrhagic necrosis in sections of large tumors, but is unable to slow the overall tumor 
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growth.  We have found that treatment with CA4P three hours before treatment with 177Lu-LCP 
increases both the accumulation and retention of 177Lu-LCP in the tumor, increasing the overall dose of 
radiation to the tumor cells.  The increased dose in the tumor helps maintain the apoptosis caused by 
the CA4P, leading to significant tumor growth inhibition in this aggressive model.   
The moderate success of this combination therapy using the model radionuclide 177Lu prompted 
us to compare it to 90Y, a radionuclide with a higher emission of beta energy resulting in a longer path 
length of the beta particle in tissue.  In a large tumor with inhomogenously delivered nanoparticles, the 
longer path length allows damage to cells in regions where nanoparticle accumulation is low.  In 
addition, the high beta energy from 90Y provides grater damage per event than 177Lu.  We found that 
combination therapy with 90Y-LCP and CA4P decreased tumor growth rate significantly more than 177Lu-
LCP + CA4P, supporting our hypothesis.  Seven days after treatment with 90Y-LCP + CA4P, these large, 
aggressive tumors were still slowly growing, although there was massive apoptosis and loss of fibroblast 
structure throughout the tumor.  At this point, treatment with a low dose of cisplatin-loaded 
nanoparticles—at a dose that was ineffective in untreated tumors of a similar size—caused a near-total 
inhibition of tumor growth until cessation of treatment. 
5.2: Significance and Novelty of Current Studies 
As stated above, the high drug loading window of isotope-loaded LCP has the potential to 
overcome the significant barrier of nanoparticle scale-up.  The ability for LCP to encapsulate a number of 
therapeutic or theranostic isotopes with alone or in combination with other therpautics—as 
demonstrated with 64Cu-GMP-LCP—provides a huge range of applications for this platform. 
Internal radiation therapy provides an advantage over chemotherapy because while 
chemotherapy must be delivered into a cell to provide its effect, beta particles (or other decay products) 
can travel and deposit energy many cell lengths away from the source.  Because nanoparticles are not 
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homogenously delivered in vivo, radiation therapy is well-equipped to maximize the number of cells 
receiving treatment.  We have shown in Chapter 2 that although nanoparticles are delivered to the 
tumor inhomogenously, nearly all cells in the analyzed sections are within just 50 μm of the nearest 
nanoparticle, suggesting that all cells are within striking distance of a beta decay from 177Lu, which has 
an average beta path length of 200-300 μm. 
 Regarding our combination therapy, the ability of CA4P to increase nanoparticle accumulation 
and retention in tumors can not only be extended to other versions of LCP, but can potentially be 
carried out in combination with completely different nanoparticle formulations.  By allowing greater 
nanoparticle accumulation while subsequently causing massive areas of apoptosis in tumors, CA4P has 
the potential to become a player alongside nanoparticle formulations in the clinic.   
5.3: Future Expectations 
Clinical implementation of this combination therapy must be modified to minimize systemic 
toxicity.  While intravenous administration of 90Y-LCP presents a good model of internal radiation 
therapy’s effectiveness in combination with CA4P, the well-known uptake of nanoparticles into clearing 
organs presents a compelling argument against this injection route.  Perhaps the best future use for 
177Lu/90Y-LCP is in selective internal radiation therapy (SIRT) [128, 129].  SIRT locally delivers 90Y-
microspheres around primary or metastatic tumors in the liver via a catheter placed into the hepatic 
artery.  The large size of the microspheres prevents them from entering the tumor capillaries, so a larger 
dose must be given in order to provide treatment to all tumor cells, resulting in off-target toxicity to the 
liver and lung.  Local delivery of 177Lu/90Y-LCP via hepatic catheter may result in better tumor 
penetration than 90Y-microspheres and less off-target dose than systemic administration of LCP, 
increasing the dose to the hepatic tumor while decreasing off-target effects.  Combination therapy with 
CA4P against stroma-rich, desmoplastic tumors would not only cause massive apoptosis in the tumor 
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centers, but also induce an increased accumulation of nanoparticles in the tumor and prime the tumor 
microenvironment for further treatment using small molecule drugs such as cisplatin that are ineffective 
without combination therapy. 
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